<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Kadcyla II-45 EN PIclean</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
h3
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:13.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:13.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-weight:bold;
	font-style:italic;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Comment Text Char Char Char Char Char Char1 Ch\,Comment Text Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char Char1 Char\,Comment Text Char2 Char Char\,Comment Text Char2 Char Char Char Char";
	mso-style-link:"Comment Text Char1\,Comment Text Char Char Char Char Char Char1 Ch Char\,Comment Text Char Char1 Char\,Comment Text Char Char1 Char Char Char\,Comment Text Char1 Char Char Char Char1 Char Char\,Comment Text Char2 Char Char Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
span.MsoPageNumber
	{font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:3.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.75in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:1.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.75in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	color:windowtext;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.25in;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;
	color:windowtext;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p
	{margin-right:0in;
	margin-bottom:3.75pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";
	color:windowtext;}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:10.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;
	color:windowtext;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	color:windowtext;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	color:windowtext;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.Annex, li.Annex, div.Annex
	{mso-style-name:Annex;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.Description, li.Description, div.Description
	{mso-style-name:Description;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.HangingIndent, li.HangingIndent, div.HangingIndent
	{mso-style-name:"Hanging Indent";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.AnnexHeading, li.AnnexHeading, div.AnnexHeading
	{mso-style-name:"Annex Heading";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char";}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1\,Comment Text Char Char Char Char Char Char1 Ch Char\,Comment Text Char Char1 Char\,Comment Text Char Char1 Char Char Char\,Comment Text Char1 Char Char Char Char1 Char Char\,Comment Text Char2 Char Char Char";
	mso-style-link:"Comment Text\,Comment Text Char Char Char Char Char Char1 Ch\,Comment Text Char Char1\,Comment Text Char Char1 Char Char\,Comment Text Char1 Char Char Char Char1 Char\,Comment Text Char2 Char Char\,Comment Text Char2 Char Char Char Char";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
p.Paragraph, li.Paragraph, div.Paragraph
	{mso-style-name:Paragraph;
	mso-style-link:"Paragraph Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
p.TextTi12, li.TextTi12, div.TextTi12
	{mso-style-name:"Text\:Ti12";
	mso-style-link:"Text\:Ti12 Char1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
span.TextTi12Char1
	{mso-style-name:"Text\:Ti12 Char1";
	mso-style-link:"Text\:Ti12";
	font-family:"Arial",sans-serif;}
p.BibliXrefAr9, li.BibliXrefAr9, div.BibliXrefAr9
	{mso-style-name:"BibliXref\:Ar9";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	mso-style-link:"Table Title Char";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;}
span.TableTitleChar
	{mso-style-name:"Table Title Char";
	mso-style-link:"Table Title";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
p.TableFooter, li.TableFooter, div.TableFooter
	{mso-style-name:"Table Footer";
	mso-style-link:"Table Footer Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:8.5pt;
	margin-left:.15in;
	text-indent:-.15in;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.ParagraphChar
	{mso-style-name:"Paragraph Char";
	mso-style-link:Paragraph;
	font-family:"Arial",sans-serif;}
p.FigureTitle, li.FigureTitle, div.FigureTitle
	{mso-style-name:"Figure Title";
	margin-top:2.0pt;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.75in;
	text-indent:-.75in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;}
p.FigureHolder, li.FigureHolder, div.FigureHolder
	{mso-style-name:"Figure Holder";
	mso-style-link:"Figure Holder Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
span.TableFooterChar
	{mso-style-name:"Table Footer Char";
	mso-style-link:"Table Footer";
	font-family:"MS Mincho";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.CommentTextChar3
	{mso-style-name:"Comment Text Char3\,Comment Text Char Char Char Char Char Char1 Ch Char1\,Comment Text Char Char1 Char Char Char1\,Comment Text Char Char1 Char1\,Comment Text Char1 Char Char Char Char1 Char Char1\,Comment Text Char2 Char Char Char1";
	font-family:"Times New Roman",serif;}
p.Hd4, li.Hd4, div.Hd4
	{mso-style-name:"Hd\:4";
	margin-top:5.65pt;
	margin-right:0in;
	margin-bottom:2.85pt;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;
	font-weight:bold;
	font-style:italic;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Times New Roman",serif;}
p.NoSpacing1, li.NoSpacing1, div.NoSpacing1
	{mso-style-name:"No Spacing1";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
p.ZchnZchn, li.ZchnZchn, div.ZchnZchn
	{mso-style-name:"Zchn Zchn";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:12.0pt;
	font-size:10.0pt;
	font-family:"Verdana",sans-serif;
	color:windowtext;}
p.Revision1, li.Revision1, div.Revision1
	{mso-style-name:Revision1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.LUTOlist-bullets, li.LUTOlist-bullets, div.LUTOlist-bullets
	{mso-style-name:"LUTO list - bullets";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:59.55pt;
	text-indent:-17.0pt;
	line-height:110%;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
p.LightShading-Accent51, li.LightShading-Accent51, div.LightShading-Accent51
	{mso-style-name:"Light Shading - Accent 51";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
p.ColorfulShading-Accent11, li.ColorfulShading-Accent11, div.ColorfulShading-Accent11
	{mso-style-name:"Colorful Shading - Accent 11";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
p.MediumGrid2-Accent11, li.MediumGrid2-Accent11, div.MediumGrid2-Accent11
	{mso-style-name:"Medium Grid 2 - Accent 11";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	color:windowtext;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Calibri",sans-serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
p.NoteHeading1, li.NoteHeading1, div.NoteHeading1
	{mso-style-name:"Note Heading1";
	mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading1";
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.ParagraphList, li.ParagraphList, div.ParagraphList
	{mso-style-name:"Paragraph List";
	mso-style-link:"Paragraph List Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	line-height:15.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
p.ParagraphSpace, li.ParagraphSpace, div.ParagraphSpace
	{mso-style-name:"Paragraph Space";
	mso-style-link:"Paragraph Space Char";
	margin:0in;
	line-height:6.0pt;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	color:windowtext;}
span.ParagraphListChar
	{mso-style-name:"Paragraph List Char";
	mso-style-link:"Paragraph List";
	font-family:"Arial",sans-serif;}
span.ParagraphSpaceChar
	{mso-style-name:"Paragraph Space Char";
	mso-style-link:"Paragraph Space";
	font-family:"Arial",sans-serif;}
span.FigureHolderChar
	{mso-style-name:"Figure Holder Char";
	mso-style-link:"Figure Holder";
	font-family:"Arial",sans-serif;}
p.SAS8, li.SAS8, div.SAS8
	{mso-style-name:"SAS 8";
	margin:0in;
	line-height:7.5pt;
	font-size:8.0pt;
	font-family:"Courier New";
	color:windowtext;
	letter-spacing:-.5pt;}
p.FPIHeading, li.FPIHeading, div.FPIHeading
	{mso-style-name:"FPI Heading";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:2.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:windowtext;
	text-transform:uppercase;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:.5in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in'>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'><b>ANNEX I</b></p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=Annex>SUMMARY OF PRODUCT CHARACTERISTICS</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif;color:green'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla 100&nbsp;mg powder for concentrate for solution for
infusion.</p>

<p class=MsoNormal>Kadcyla 160&nbsp;mg powder for concentrate for solution for
infusion.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Kadcyla 100 mg powder for concentrate for solution for
infusion</u></p>

<p class=MsoNormal style='text-autospace:none'>One vial of powder for
concentrate for solution for infusion contains 100 mg of trastuzumab emtansine.
After reconstitution one vial of 5 mL solution contains 20 mg/mL of trastuzumab
emtansine (see section 6.6).</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><u>Kadcyla 160 mg powder for
concentrate for solution for infusion</u></p>

<p class=MsoNormal style='text-autospace:none'>One vial of powder for
concentrate for solution for infusion contains 160 mg of trastuzumab emtansine.
After reconstitution one vial of 8 mL solution contains 20 mg/mL of trastuzumab
emtansine (see section 6.6).</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>Trastuzumab emtansine is an
antibody&#8209;drug conjugate that contains trastuzumab, a humanised IgG1
monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension
culture, covalently linked to DM1, a microtubule inhibitor, via the stable
thioether linker MCC (4&#8209;[N&#8209;maleimidomethyl]&nbsp;cyclohexane&#8209;1&#8209;carboxylate).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For the full list of excipients, see section&nbsp;6.1.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Powder for concentrate for solution for infusion.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>White to off&#8209;white lyophilised powder.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b><span style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b>CLINICAL
PARTICULARS</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Early Breast Cancer (EBC)</u></p>

<p class=MsoNormal>Kadcyla, as a single agent, is indicated for the adjuvant
treatment of adult patients with HER2-positive early breast cancer who have
residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant
taxane-based and HER2-targeted therapy.</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><u>Metastatic Breast Cancer (MBC)</u></p>

<p class=MsoNormal>Kadcyla, as a single agent, is indicated for the treatment
of adult patients with HER2-positive, </p>

<p class=MsoNormal>unresectable locally advanced or metastatic breast cancer
who previously received trastuzumab and a taxane, separately or in combination.
Patients should have either:</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Received
prior therapy for locally advanced or metastatic disease, or</p>

<p class=MsoNormal><span lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed
disease recurrence during or within six months of completing adjuvant therapy.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology
and method of administration</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla should only be prescribed by a physician and
administered as an intravenous infusion under the supervision of a healthcare
professional who is experienced in the treatment of cancer patients (i.e. <span
lang=EN-GB>prepared to manage allergic/anaphylactic infusion reactions and </span><span
lang=EN-GB>in an environment where full resuscitation facilities are
immediately available (see section 4.4))</span>.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Patients treated with trastuzumab emtansine should have HER2
positive tumour status, defined as a score of 3&nbsp;+ by immunohistochemistry
(IHC) or a ratio of&nbsp;&#8805;&nbsp;2.0 by in situ hybridization (ISH) or by
fluorescence in situ hybridization (FISH) assessed by a CE-marked In Vitro Diagnostic
(IVD) medical device. If a CE-marked IVD is not available, the HER2-status
should be assessed by an alternate validated test. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>In order to prevent medicinal
product errors it is important to check the vial labels to ensure that the
medicinal product being prepared and administered is Kadcyla (trastuzumab
emtansine) and not Herceptin (trastuzumab).</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Posology</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The recommended dose of
trastuzumab emtansine is 3.6&nbsp;mg/kg bodyweight administered as an
intravenous infusion every&nbsp;3&nbsp;weeks (21&#8209;day cycle). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The initial dose should be administered as a 90&nbsp;minute
intravenous infusion. Patients should be observed during the infusion and for
at least 90&nbsp;minutes following the initial infusion for fever, chills, or
other infusion&#8209;related reactions. The infusion site should be closely
monitored for possible subcutaneous infiltration during administration (see
section&nbsp;4.8).</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal>If the prior infusion was well tolerated, subsequent doses
of trastuzumab emtansine may be administered as 30&nbsp;minute infusions.
Patients should be observed during the infusion and for at least
30&nbsp;minutes after infusion.</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal>The infusion rate of trastuzumab emtansine should be slowed
or interrupted if the patient develops infusion&#8209;related symptoms (see
sections&nbsp;4.4 and 4.8). Trastuzumab emtansine should be discontinued in
case of life&#8209;threatening infusion reactions.</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal><u>Duration of treatment</u></p>

<p class=MsoNormal><i><u><span style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=MsoNormal><i>Early Breast Cancer (EBC)</i></p>

<p class=MsoNormal>Patients should receive treatment for a total of 14 cycles unless
there is disease recurrence or unmanageable toxicity.</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>Metastatic Breast Cancer (MBC)</i></p>

<p class=MsoNormal>Patients should receive treatment until disease progression
or unmanageable toxicity.</p>

<p class=MsoNormal><i>Dose modification</i></p>

<p class=MsoNormal>Management of symptomatic adverse reactions may require
temporary interruption, dose reduction, or treatment discontinuation of
trastuzumab emtansine as per guidelines provided in text and
Tables&nbsp;1&nbsp;and 2&nbsp;.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Trastuzumab emtansine dose should not be re&#8209;escalated
after a dose reduction is made.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose
reduction schedule</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='background:white;border-collapse:collapse;border:none'>
 <tr>
  <td width=272 valign=top style='width:204.1pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>Dose <span style='color:black'>reduction schedule</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>(Starting dose is 3.6 mg/kg)</span></b></p>
  </td>
  <td width=209 style='width:156.8pt;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span style='color:black'>Dose&nbsp; to be administered</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=272 valign=top style='width:204.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>First
  dose reduction</span></p>
  </td>
  <td width=209 valign=top style='width:156.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>3&nbsp;mg/kg</span></p>
  </td>
 </tr>
 <tr>
  <td width=272 valign=top style='width:204.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Second
  dose reduction</span></p>
  </td>
  <td width=209 valign=top style='width:156.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>2.4&nbsp;mg/kg</span></p>
  </td>
 </tr>
 <tr>
  <td width=272 valign=top style='width:204.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Requirement
  for further dose reduction</span></p>
  </td>
  <td width=209 valign=top style='width:156.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span style='color:black'>Discontinue
  treatment</span></p>
  </td>
 </tr>
</table>

<p class=TextTi12 style='line-height:14.0pt'><b><i><span lang=FR-CH
style='font-family:"Times New Roman",serif'>&nbsp;</span></i></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose
Modification Guidelines</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=604
 style='width:452.8pt;border-collapse:collapse'>
 <tr style='height:15.75pt'>
  <td colspan=3 valign=bottom style='border:solid windowtext 1.0pt;background:
  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b>Dose <span style='color:black'>Modifications for Patients with EBC</span></b></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=bottom style='border:solid windowtext 1.0pt;border-top:none;
  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Adverse reaction</b></p>
  </td>
  <td valign=bottom style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-CARRIBEAN>Severity</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Treatment modification</b></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td rowspan=2 valign=top style='border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>Thrombocytopenia</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 2-3 on day of scheduled
  treatment<br>
  (25,000 to &lt; 75,000/mm<sup>3</sup>)</span></p>
  </td>
  <td valign=bottom style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> until platelet count recovers to</span><span
  style='font-family:Symbol'> &pound;</span><span lang=EN-CARRIBEAN> Grade 1
  (&#8805; 75,000/mm<sup>3</sup>), and then treat at the same dose level. If a
  patient requires 2 delays due to thrombocytopenia, consider reducing dose by
  one level.</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 4 at any time<br>
  &lt; 25,000/mm<sup>3</sup></span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> until platelet count recovers to </span><span
  style='font-family:Symbol'>&pound;</span><span lang=EN-CARRIBEAN> Grade 1
  (&#8805; 75,000/mm<sup>3</sup>), and then reduce one dose level.</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td rowspan=2 valign=top style='border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>Increased Alanine Transaminase (ALT)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 2-3<br>
  (&gt; 3.0 to &#8804; 20</span><span style='font-family:Symbol'>&acute;</span><span
  lang=EN-CARRIBEAN> ULN on day of scheduled treatment)</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> until ALT recovers to Grade &#8804; 1, and
  then reduce one dose level</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 4<br>
  (&gt; 20 </span><span style='font-family:Symbol'>&acute;</span><span
  lang=EN-CARRIBEAN> ULN at any time)</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td rowspan=3 valign=top style='border:solid windowtext 1.0pt;border-top:
  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt'>
  <p class=MsoNormal>Increased Aspartate Transaminase (AST)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 2 <br>
  (&gt; 3.0 to &#8804; 5</span><span style='font-family:Symbol'>&acute;</span><span
  lang=EN-CARRIBEAN> ULN on day of scheduled treatment) </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> until AST recovers to Grade </span><span
  style='font-family:Symbol'>&pound;</span><span lang=EN-CARRIBEAN> 1, and then
  treat at the same dose level</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 3 <br>
  (&gt; 5 to &#8804; 20</span><span style='font-family:Symbol'>&acute;</span><span
  lang=EN-CARRIBEAN> ULN on day of scheduled treatment) </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> until AST recovers to Grade &#8804; 1, and
  then reduce one dose level</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 4 <br>
  (&gt; 20 </span><span style='font-family:Symbol'>&acute;</span><span
  lang=EN-CARRIBEAN> ULN at any time) </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td rowspan=2 valign=top style='border:solid windowtext 1.0pt;border-top:
  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt'>
  <p class=MsoNormal>Hyperbilirubinemia</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>TBILI <br>
  &gt; 1.0 to &#8804; 2.0</span><span style='font-family:Symbol'>&acute; </span><span
  lang=EN-CARRIBEAN>the ULN on day of scheduled treatment </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> until total bilirubin recovers to &#8804;
  1.0&times; ULN, and then reduce one dose level</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>TBILI <br>
  &gt; 2</span><span style='font-family:Symbol'>&acute;</span><span
  lang=EN-CARRIBEAN> ULN at any time </span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>Drug Induced Liver Injury (DILI)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>Serum transaminases &gt; 3 x ULN and concomitant total
  bilirubin &gt; 2<span style='font-family:Symbol'>&acute;</span> ULN</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal>Permanently discontinue trastuzumab emtansine<span
  style='font-family:"Calibri",sans-serif'> </span>in the absence of another
  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver
  metastasis or concomitant medication</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border:solid windowtext 1.0pt;border-bottom:none;
  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt'>
  <p class=MsoNormal>Nodular Regenerative Hyperplasia (NRH)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>All Grades</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal>Permanently discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border:solid windowtext 1.0pt;border-bottom:none;
  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:7.75pt'>
  <p class=MsoNormal>Peripheral Neuropathy</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>Grade 3-4</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal>Do not administer trastuzumab emtansine until resolution <span
  style='font-family:Symbol'>&pound; </span>Grade 2</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td rowspan=4 valign=top style='border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>Left Ventricular Dysfunction </p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>LVEF &lt; 45%</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN> .<br>
  Repeat LVEF assessment within 3 weeks. </span>If LVEF &lt; 45% is confirmed,
  discontinue trastuzumab emtansine.</p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>LVEF 45% to &lt; 50% and decrease
  is &#8805; 10% points from baseline*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Do not administer </span>trastuzumab
  emtansine.<span lang=EN-CARRIBEAN><br>
  Repeat LVEF assessment within 3 weeks. If the LVEF remains &lt; 50% and has
  not recovered to &lt; 10% points from baseline, discontinue </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN>.</span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>LVEF 45% to &lt; 50% and decrease
  is &lt; 10% points from baseline*</span></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Continue treatment with </span>trastuzumab
  emtansine<span lang=EN-CARRIBEAN>. <br>
  Repeat LVEF assessment within 3 weeks. </span></p>
  </td>
 </tr>
 <tr style='height:7.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:7.75pt'>
  <p class=MsoNormal>LVEF &#8805; 50%</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;height:7.75pt'>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Continue treatment with </span>trastuzumab
  emtansine</p>
  </td>
 </tr>
 <tr style='height:97.5pt'>
  <td valign=top style='border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:97.5pt'>
  <p class=MsoNormal>Heart Failure</p>
  </td>
  <td valign=bottom style='border:none;border-right:solid windowtext 1.0pt;
  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:97.5pt'>
  <p class=MsoNormal>Symptomatic CHF,</p>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 3-4 LVSD or Grade 3-4 heart
  failure, or</span></p>
  <p class=MsoNormal><span lang=EN-CARRIBEAN>Grade 2 heart failure <br>
  accompanied by LVEF &lt;45% </span></p>
  </td>
  <td valign=top style='border:none;border-right:solid windowtext 1.0pt;
  padding:0in 0in 0in 0in;height:97.5pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:35.35pt'>
  <td valign=top style='border:solid windowtext 1.0pt;border-bottom:none;
  padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt'>
  <p class=MsoNormal>Pulmonary Toxicity</p>
  </td>
  <td valign=top style='border-top:solid windowtext 1.0pt;border-left:none;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:35.35pt'>
  <p class=MsoNormal>Interstitial lung disease (ILD) or pneumonitis</p>
  </td>
  <td valign=top style='border-top:solid windowtext 1.0pt;border-left:none;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:35.35pt'>
  <p class=MsoNormal>Permanently discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:35.35pt'>
  <td rowspan=2 valign=top style='border:solid windowtext 1.0pt;border-bottom:
  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:35.35pt'>
  <p class=MsoNormal>Radiotherapy-Related Pneumonitis</p>
  </td>
  <td valign=top style='border-top:solid windowtext 1.0pt;border-left:none;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:35.35pt'>
  <p class=MsoNormal>Grade 2</p>
  </td>
  <td valign=top style='border-top:solid windowtext 1.0pt;border-left:none;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:35.35pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine if not resolving with
  standard treatment</p>
  </td>
 </tr>
 <tr style='height:35.35pt'>
  <td valign=top style='border-top:solid windowtext 1.0pt;border-left:none;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:35.35pt'>
  <p class=MsoNormal>Grade 3-4</p>
  </td>
  <td valign=top style='border-top:solid windowtext 1.0pt;border-left:none;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 0in 0in 0in;
  height:35.35pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td colspan=3 valign=bottom style='border:solid windowtext 1.0pt;background:
  #BFBFBF;padding:1.5pt 0in 1.5pt 0in;height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  style='color:black'>Dose Modifications for Patients with MBC</span></b></p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=bottom style='border:solid windowtext 1.0pt;border-top:none;
  padding:1.5pt 0in 1.5pt 0in;height:15.75pt'>
  <p class=MsoNormal><b>Adverse reaction</b></p>
  </td>
  <td valign=bottom style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal><b><span lang=EN-CARRIBEAN>Severity</span></b></p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><b>Treatment
  modification</b></p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td rowspan=2 valign=top style='border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;
  height:15.75pt'>
  <p class=MsoNormal>Thrombocytopenia</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 3 </p>
  <p class=MsoNormal>(25,000 to <span style='font-family:Symbol'>&lt;</span>&nbsp;50,000/mm<sup>3</sup>)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Do not
  administer trastuzumab emtansine until platelet count recovers to <span
  style='font-family:Symbol'>&pound;</span> Grade&nbsp;1 (&#8805; 75,000/mm<sup>3</sup>),
  and then treat at the same dose level</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 4</p>
  <p class=MsoNormal><span style='font-family:Symbol'>(&lt;</span>&nbsp;25,000/mm<sup>3</sup>)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Do not
  administer trastuzumab emtansine until platelet count recovers to <span
  style='font-family:Symbol'>&pound;</span> Grade&nbsp;1 (&#8805; 75,000/mm<sup>3</sup>),
  and then reduce one dose level</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td rowspan=3 valign=top style='border:solid windowtext 1.0pt;padding:1.5pt 0in 1.5pt 0in;
  height:15.75pt'>
  <p class=MsoNormal>Increased Transaminase (AST/ALT)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 2<br>
  (<span style='font-family:Symbol'>&gt;</span>&nbsp;2.5 to &#8804; 5<span
  style='font-family:Symbol'>&acute;</span> the ULN)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Treat at
  the same dose level</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 3<br>
  (<span style='font-family:Symbol'>&gt;</span>&nbsp;5 to &#8804; 20<span
  style='font-family:Symbol'>&acute;</span> the ULN)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Do not administer trastuzumab emtansine until AST/ALT
  recovers to Grade &#8804; 2, and then reduce one dose level</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 4<br>
  (<span style='font-family:Symbol'>&gt;</span>&nbsp;20<span style='font-family:
  Symbol'>&acute;</span> the ULN)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td rowspan=3 valign=top style='border:solid windowtext 1.0pt;border-top:
  none;padding:1.5pt 2.25pt 1.5pt 2.25pt;height:15.75pt'>
  <p class=MsoNormal>Hyperbilirubinemia</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 2<br>
  (<span style='font-family:Symbol'>&gt;</span>&nbsp;1.5 to &#8804; 3<span
  style='font-family:Symbol'>&acute;</span> the ULN)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Do not administer trastuzumab emtansine until total
  bilirubin recovers to Grade &#8804; 1, and then treat at the same dose level.</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 3<br>
  (<span style='font-family:Symbol'>&gt;</span>&nbsp;3 to &#8804; 10<span
  style='font-family:Symbol'>&acute;</span> the ULN)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Do not administer trastuzumab emtansine until total
  bilirubin recovers to Grade &#8804; 1 and then reduce one dose level.</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Grade 4<br>
  (<span style='font-family:Symbol'>&gt;</span>&nbsp;10<span style='font-family:
  Symbol'>&acute;</span> the ULN)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Discontinue trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Drug Induced Liver Injury (DILI)</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Serum transaminases &gt; 3 x ULN and concomitant total
  bilirubin &gt; 2<span style='font-family:Symbol'>&acute;</span> ULN</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Permanently discontinue trastuzumab emtansine<span
  style='font-family:"Calibri",sans-serif'> </span>in the absence of another
  likely cause for the elevation of liver enzymes and bilirubin, e.g. liver
  metastasis or concomitant medication</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td rowspan=5 valign=top style='border:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Left Ventricular Dysfunction </p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Symptomatic CHF</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Discontinue
  trastuzumab emtansine</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>LVEF &lt;40%</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Do not
  administer trastuzumab emtansine.</p>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Repeat
  LVEF assessment within 3 weeks. If LVEF &lt;40% is confirmed, discontinue trastuzumab
  emtansine</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>LVEF 40% to &#8804; 45% and decrease is &#8805; 10% points
  from baseline</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Do not
  administer trastuzumab emtansine.</p>
  <p class=MsoNormal>Repeat LVEF assessment within 3 weeks. If the LVEF has not
  recovered to within 10% points from baseline, discontinue trastuzumab
  emtansine.</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>LVEF 40% to &#8804; 45% and decrease is &lt; 10% points
  from baseline</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'>Continue
  treatment with<span style='color:#0000CC'> </span>trastuzumab emtansine<i><span
  style='color:#002060'>.</span></i></p>
  <p class=MsoNormal>Repeat LVEF assessment within 3 weeks.</p>
  </td>
 </tr>
 <tr style='height:15.75pt'>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>LVEF &gt; 45%</p>
  </td>
  <td valign=top style='border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:1.5pt 2.25pt 1.5pt 2.25pt;
  height:15.75pt'>
  <p class=MsoNormal>Continue treatment with trastuzumab emtansine<i><span
  style='color:#002060'>.</span></i></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-top:12.0pt'><span style='font-size:9.0pt'>ALT&nbsp;</span><span
style='font-size:9.0pt;font-family:Symbol'>=</span><span style='font-size:9.0pt'>&nbsp;alanine
transaminase; AST&nbsp;</span><span style='font-size:9.0pt;font-family:Symbol'>=</span><span
style='font-size:9.0pt'>&nbsp;aspartate transaminase, CHF = congestive heart
failure, LVEF&nbsp;</span><span style='font-size:9.0pt;font-family:Symbol'>=</span><span
style='font-size:9.0pt'>&nbsp;left ventricular ejection fraction, LVSD&nbsp;</span><span
style='font-size:9.0pt;font-family:Symbol'>=</span><span style='font-size:9.0pt'>&nbsp;left
ventricular systolic dysfunction, TBILI = Total Bilirubin, ULN&nbsp;</span><span
style='font-size:9.0pt;font-family:Symbol'>=</span><span style='font-size:9.0pt'>&nbsp;upper
limit of normal</span></p>

<p class=MsoNormal style='line-height:14.0pt;page-break-after:avoid'><span
style='font-size:9.0pt'>* Prior to starting trastuzumab emtansine treatment. </span></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>Delayed or missed dose</i></p>

<p class=MsoNormal>If a planned dose is missed, it should be administered as
soon as possible; without waiting until the next planned cycle. The schedule of
administration should be adjusted to maintain a 3&#8209;week interval between
doses. The next dose should be administered in accordance with the dosing
recommendations above.</p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Peripheral neuropathy</i></p>

<p class=MsoNormal>Trastuzumab emtansine should be temporarily discontinued in
patients experiencing Grade 3 or 4 peripheral neuropathy until resolution to
&#8804; Grade 2. At retreatment a dose reduction may be considered according to
the dose reduction schedule (see Table 1).</p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Special populations</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Elderly patients </i></p>

<p class=MsoNormal>No dose adjustment is required in patients aged
&#8805;&nbsp;65 years. There are insufficient data to establish the safety and
efficacy in patients &#8805;&nbsp;75 years due to limited data in this
subgroup.<span style='font-size:10.0pt;font-family:"Arial",sans-serif;
color:#222222;background:white'> </span>Population pharmacokinetic analysis
indicates that age does not have a clinically meaningful effect on the
pharmacokinetics of trastuzumab emtansine (see sections 5.1 and 5.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Renal impairment</i></p>

<p class=MsoNormal style='page-break-after:avoid'>No adjustment to the starting
dose is needed in patients with mild or moderate renal impairment (see section
5.2). The potential need for dose adjustment in patients with severe renal
impairment cannot be determined due to insufficient data and therefore patients
with severe renal impairment should be monitored carefully.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Hepatic impairment</i></p>

<p class=MsoNormal>No adjustment to the starting dose is required for patients
with mild or moderate hepatic impairment.&nbsp; Trastuzumab emtansine has not
been studied in patients with severe hepatic impairment.&nbsp; Treatment of
patients with hepatic impairment should be undertaken with caution due to known
hepatotoxicity observed with trastuzumab emtansine (see section 4.4 and 5.2).</p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Paediatric </span></i><i>population</i></p>

<p class=MsoNormal>The safety and efficacy in children and adolescents below
18&nbsp;years of age have not been established as there is no relevant use in
the <span lang=EN-GB>paediatric </span>population for the indication of breast
cancer . </p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Method of administration</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>Kadcyla is for intravenous use. Trastuzumab emtansine must
be reconstituted and diluted by a healthcare professional and administered as
an intravenous infusion. It must not be administered as an intravenous push or
bolus.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For instructions on reconstitution and dilution of the
medicinal product before administration, see section&nbsp;6.6.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b><u><span
 style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Hypersensitivity to the active substance or to any of the
excipients listed in section&nbsp;6.1.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In order to improve traceability of biological medicinal
products, the tradename and the batch number of the administered product should
be clearly recorded (or stated) in the patient file.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In order to prevent medicinal product errors it is important
to check the vial labels to ensure that the medicinal product being prepared
and administered is Kadcyla (trastuzumab emtansine) and not Herceptin
(trastuzumab).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Thrombocytopenia</i></p>

<p class=MsoNormal>Thrombocytopenia, or decreased platelet counts, was commonly
reported with trastuzumab emtansine and was the most common adverse reaction
leading to treatment discontinuation, dose reduction, and dose interruption
(see section&nbsp;4.8). In clinical studies, the incidence and severity of
thrombocytopenia were higher in Asian patients (see section 4.8).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>It is recommended that platelet counts are monitored prior
to each trastuzumab emtansine dose. Patients with thrombocytopenia
(&#8804;&nbsp;100,000/mm<sup>3</sup>) and patients on anti&#8209;coagulant
treatment (e.g. warfarin, heparin, low molecular weight heparins) should be
monitored closely while on trastuzumab emtansine treatment. Trastuzumab
emtansine has not been studied in patients with platelet counts
&#8804;&nbsp;100,000/mm<sup>3</sup> prior to initiation of treatment. In the
event of decreased platelet count to Grade&nbsp;3 or greater
(&lt;&nbsp;50,000/mm<sup>3</sup>), do not administer trastuzumab emtansine
until platelet counts recover to Grade&nbsp;1 (&#8805;&nbsp;75,000/mm<sup>3</sup>)
(see section&nbsp;4.2). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Haemorrhage</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Cases of haemorrhagic events,
including central nervous system, respiratory and gastrointestinal haemorrhage,
have been reported with trastuzumab emtansine treatment. Some of these bleeding
events resulted in fatal outcomes. In some of the observed cases the patients
had thrombocytopenia, or were also receiving anti-coagulant therapy or
antiplatelet therapy; in others there were no known additional risk factors.
Use caution with these agents and consider additional monitoring when
concomitant use is medically necessary.</p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Hepatotoxicity</i></p>

<p class=MsoNormal>Hepatotoxicity, predominantly in the form of asymptomatic
increases in the concentrations of serum transaminases (Grade&nbsp;1&#8209;4&nbsp;transaminitis),
has been observed during treatment with trastuzumab emtansine in clinical
studies (see section&nbsp;4.8). Transaminase elevations were generally
transient with peak elevation at day 8 after administration of therapy and
subsequent recovery to Grade 1 or less prior to the next cycle. A cumulative
effect on transaminases has also been observed (the proportion of patients with
Grade 1-2 ALT/AST abnormalities increases with successive cycles). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Patients with elevated transaminases improved to Grade 1 or
normal within 30 days of the last dose of trastuzumab emtansine in the majority
of the cases (see section 4.8). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Serious hepatobiliary disorders, including nodular
regenerative hyperplasia (NRH) of the liver and some with a fatal outcome due
to drug-induced liver injury have been observed in patients treated with
trastuzumab emtansine. Observed cases may have been confounded by comorbidities
and/or concomitant medicinal products with known hepatotoxic potential.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Liver function should be monitored prior to initiation of
treatment and each dose. Patients with baseline elevation of ALT (e.g. due to
liver metastases)&nbsp;may be predisposed to liver injury with a higher risk of
a Grade 3-5 hepatic event or liver function test increase. Dose reductions or
discontinuation for increased serum transaminases and total bilirubin are
specified in section 4.2.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Cases of nodular regenerative hyperplasia (NRH) of the liver
have been identified from liver biopsies in patients treated with trastuzumab
emtansine. NRH is a rare liver condition characterised by widespread benign
transformation of hepatic parenchyma into small regenerative nodules; NRH may
lead to non&#8209;cirrhotic portal hypertension. Diagnosis of NRH can be
confirmed only by histopathology. NRH should be considered in all patients with
clinical symptoms of portal hypertension and/or cirrhosis-like pattern seen on
the computed tomography (CT) scan of the liver but with normal transaminases
and no other manifestations of cirrhosis. Upon diagnosis of NRH, trastuzumab
emtansine treatment must be permanently discontinued. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Trastuzumab emtansine has not been studied in patients with
serum transaminases&nbsp;&gt;&nbsp;2.5<b>&nbsp;</b><span style='font-family:
Symbol'>&acute;</span>&nbsp;ULN or total bilirubin&nbsp;&gt;&nbsp;1.5<b>&nbsp;</b><span
style='font-family:Symbol'>&acute;</span>&nbsp;ULN prior to initiation of
treatment. Treatment in patients with serum transaminases&nbsp;&gt;&nbsp;3<b>&nbsp;</b><span
style='font-family:Symbol'>&acute;</span>&nbsp;ULN and concomitant total
bilirubin&nbsp;&gt;&nbsp;2<b>&nbsp;</b><span style='font-family:Symbol'>&acute;</span>&nbsp;ULN
should be permanently discontinued. Treatment of patients with hepatic
impairment should be undertaken with caution (see sections 4.2 and 5.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Neurotoxicity</i></p>

<p class=MsoNormal>Peripheral neuropathy, mainly Grade&nbsp;1 and predominantly
sensory, has been reported in clinical studies with trastuzumab emtansine. MBC
patients with Grade &nbsp;<span style='font-family:Symbol'>&sup3;</span>&nbsp;3
and EBC patients with Grade &nbsp;<span style='font-family:Symbol'>&sup3;</span>&nbsp;2</p>

<p class=MsoNormal style='page-break-after:avoid'>peripheral neuropathy at
baseline were excluded from clinical studies. Treatment with trastuzumab emtansine
should be temporarily discontinued in patients experiencing Grade&nbsp;3 or 4
peripheral neuropathy until symptoms resolve or improve to
&#8804;&nbsp;Grade&nbsp;2. Patients should be clinically monitored on an
ongoing basis for signs/symptoms of neurotoxicity<i>. </i></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Left ventricular
dysfunction</i> </p>

<p class=MsoNormal>Patients treated with trastuzumab emtansine are at increased
risk of developing left ventricular dysfunction. Left ventricular ejection
fraction (LVEF)&nbsp;&lt;&nbsp;40% has been observed in patients treated with
trastuzumab emtansine, and therefore symptomatic congestive heart failure (CHF)
is a potential risk (see section&nbsp;4.8). General risk factors for a cardiac
event and those identified in adjuvant breast cancer studies with trastuzumab
therapy include advancing age (&gt; 50 years), low baseline LVEF values
(&lt;&nbsp;55%), low LVEF levels prior to or following the use of paclitaxel in
the adjuvant setting, prior or concomitant use of antihypertensive medicinal
products, previous therapy with an anthracycline and high BMI (&gt; 25 kg/m<sup>2</sup>).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Standard cardiac function testing (echocardiogram or
multigated acquisition (MUGA) scanning) should be performed prior to initiation
and at regular intervals (e.g. every three months) during treatment. In
clinical studies, patients had a LVEF&nbsp;<span style='font-family:Symbol'>&sup3;</span>&nbsp;50%
at baseline. Patients with a history of congestive heart failure (CHF), serious
cardiac arrhythmia requiring treatment, history of myocardial infarction or
unstable angina within 6 months of randomization, or current dyspnoea at rest
due to advanced malignancy were excluded from clinical studies. The dose should
be delayed or treatment discontinued as necessary in cases of left ventricular
dysfunction (see section&nbsp;4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Pulmonary toxicity</i></p>

<p class=MsoNormal>Cases of interstitial lung disease (ILD), including
pneumonitis, some leading to acute respiratory distress syndrome or a fatal
outcome, have been reported in clinical studies with trastuzumab emtansine (see
section&nbsp;4.8). Signs and symptoms include dyspnoea, cough, fatigue, and
pulmonary infiltrates. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>It
is recommended that treatment with trastuzumab emtansine be permanently
discontinued in patients who are diagnosed with ILD or pneumonitis,<b><span
style='font-size:8.0pt'> </span></b>except for radiation pneumonitis in the
adjuvant setting, where trastuzumab emtansine should be permanently
discontinued for <span style='font-family:Symbol'>&sup3;</span> Grade 3 or for
Grade 2 not responding to standard treatment. (see section 4.2).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Patients with dyspnoea at rest due to complications of
advanced malignancy, co&#8209;morbidities, and receiving concurrent pulmonary
radiation therapy may be at increased risk of pulmonary events.</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Infusion-related reactions</i></p>

<p class=MsoNormal>Trastuzumab emtansine treatment has not been studied in
patients who had trastuzumab permanently discontinued due to infusion-related
reactions (IRR); treatment is not recommended for these patients. Patients
should be observed closely for infusion-related reactions, especially during
the first infusion.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Infusion-related reactions (due to cytokine release),
characterized by one or more of the following symptoms have been reported:
flushing, chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and
tachycardia. In general, these symptoms were not severe (see section 4.8). In
most patients, these reactions resolved over the course of several hours to a
day after the infusion was terminated. Treatment should be interrupted in
patients with a severe IRR until signs and symptoms resolve. Consideration for
re-treatment should be based on clinical assessment of the severity of the
reaction. Treatment must be permanently discontinued in the event of a life
threatening infusion-related reaction (see section&nbsp;4.2). </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Hypersensitivity reactions</i></p>

<p class=MsoNormal>Trastuzumab emtansine treatment has not been studied in
patients who had trastuzumab permanently discontinued due to hypersensitivity;
treatment with trastuzumab emtansine is not recommended for these patients. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Patients should be observed closely for
hypersensitivity/allergic reactions, which may have the same clinical
presentation as an IRR. Serious, anaphylactic reactions have been observed in
clinical studies with trastuzumab emtansine. Medicinal products to treat such
reactions, as well as emergency equipment, should be available for immediate
use. In the event of a true hypersensitivity reaction (in which severity of
reaction increases with subsequent infusions), trastuzumab emtansine treatment
must be permanently discontinued. </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Sodium content in
excipients</i></p>

<p class=MsoNormal>This medicinal product contains less than 1 mmol sodium (23
mg) per dose, i.e. essentially &#8216;sodium- free&#8217;.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>No formal interaction studies have been performed. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>In vitro</i> metabolism studies in human liver microsomes
suggest that DM1, a component of trastuzumab emtansine, is metabolised mainly
by CYP3A4 and, to a lesser extent, by CYP3A5.&nbsp;&nbsp; Concomitant use of
strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin,
atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
telithromycin, and voriconazole) with trastuzumab emtansine should be avoided
due to the potential for an increase in DM1 exposure and toxicity.&nbsp;
Consider an alternate medicinal product with no or minimal potential to inhibit
CYP3A4.&nbsp; If concomitant use of strong CYP3A4 inhibitors is unavoidable,
consider delaying trastuzumab emtansine treatment until the strong CYP3A4
inhibitors have cleared from the circulation (approximately 3 elimination
half-lives of the inhibitors) when possible.&nbsp; If a strong CYP3A4 inhibitor
is coadministered and trastuzumab emtansine treatment cannot be delayed,
patients should be closely monitored for adverse reactions. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.6&nbsp;&nbsp;&nbsp;&nbsp; Fertility,
pregnancy and lactation</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Contraception in males and females</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>Women of childbearing potential should use effective
contraception while receiving trastuzumab emtansine and for 7&nbsp;months
following the last dose of trastuzumab emtansine. Male patients or their female
partners should also use effective contraception.</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Pregnancy</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>There are no data from the use of trastuzumab emtansine in
pregnant women. Trastuzumab, a component of trastuzumab emtansine, can cause
foetal harm or death when administered to a pregnant woman. In the post&#8209;marketing
setting, cases of oligohydramnios, some associated with fatal pulmonary
hypoplasia, have been reported in pregnant women receiving trastuzumab. Animal
studies of maytansine, a closely related chemical entity of the same
maytansinoid class as DM1, suggest that DM1, the microtubule inhibiting
cytotoxic component of trastuzumab emtansine, is expected to be teratogenic and
potentially embryotoxic (see section 5.3).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Administration<i> </i>of trastuzumab emtansine to pregnant
women is not recommended and women should be informed of the possibility of
harm to the foetus before they become pregnant. Women who become pregnant must
immediately contact their doctor. If a pregnant woman is treated with
trastuzumab emtansine, close monitoring by a multidisciplinary team is
recommended.</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Breast&#8209;feeding</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>It is not known whether trastuzumab emtansine is excreted in
human milk. Since many medicinal products are excreted in human milk and
because of the potential for serious adverse reactions in breast&#8209;feeding
infants, women should discontinue breast&#8209;feeding prior to initiating
treatment with trastuzumab emtansine. Women may begin breast&#8209;feeding 7&nbsp;months
after concluding treatment. </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Fertility</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>No reproductive and developmental toxicology studies have
been conducted with trastuzumab emtansine. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use
machines</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal>Trastuzumab emtansine has minor influence on the ability to
drive and use machines. </p>

<p class=MsoNormal>The significance of reported adverse reactions such as
fatigue, headache, dizziness and blurred vision on the ability to drive or use
machines is unknown. Patients experiencing infusion&#8209;related reactions (flushing,
chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm, and tachycardia)
should be advised not to drive and use machines until symptoms abate.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable effects</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Summary of the safety
profile</u><u> </u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>The safety of trastuzumab
emtansine has been evaluated in 2,611&nbsp;breast cancer patients in clinical
studies. In this patient population: </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; the most
common serious ADRs (&gt; 0.5% of patients) were haemorrhage, pyrexia, thrombocytopenia,
dyspnoea, abdominal pain, musculoskeletal pain, and vomiting.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <span
style='color:black'>the most common adverse drug reactions (ADRs) (&#8805;25%)
with trastuzumab emtansine were nausea, fatigue, musculoskeletal pain,
haemorrhage, headache, transaminases increased, thrombocytopenia, and peripheral
neuropathy. The majority of ADRs reported were of Grade&nbsp;1 or 2 severity.</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; the most
common National Cancer Institute - Common Terminology Criteria for Adverse
Events (NCI-CTCAE) Grade &#8805;&nbsp;3 ADRs (&gt;&nbsp;2%) were
thrombocytopenia, increased transaminases, anaemia, neutropenia, fatigue and
hypokalaemia.</p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Tabulated list of adverse
reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal>The ADRs in 2,611&nbsp;patients treated with trastuzumab
emtansine are presented in Table&nbsp;3.&nbsp; The ADRs are listed below by
MedDRA system organ class (SOC) and categories of frequency. Frequency
categories are defined as very common (&#8805;&nbsp;1/10), common
(&#8805;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1,000 to
&lt;&nbsp;1/100), rare (&#8805;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare
(&lt;&nbsp;1/10,000) and not known (cannot be estimated from the available
data). Within each frequency grouping and SOC, adverse reactions are presented
in order of decreasing seriousness.&nbsp; ADRs were reported using NCI-CTCAE
for assessment of toxicity.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated
list of ADRs in patients treated with trastuzumab emtansine in clinical trials</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='height:15.8pt'>
   <td width=181 nowrap style='width:135.95pt;border:solid windowtext 1.0pt;
   padding:0in 4.25pt 0in 4.25pt;height:15.8pt'>
   <p class=Default align=center style='margin-left:-.05pt;text-align:center;
   text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
   style='font-size:11.0pt;color:windowtext'>System Organ Class</span></b></p>
   </td>
   <td width=140 nowrap style='width:104.9pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt'>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Very Common</span></b></p>
   </td>
   <td width=140 nowrap style='width:104.9pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt'>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Common</span></b></p>
   </td>
   <td width=127 nowrap style='width:95.6pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 4.25pt 0in 4.25pt;height:15.8pt'>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Uncommon</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='height:26.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Infections and infestations</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Urinary tract infection</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:26.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Blood and lymphatic system
  disorders</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Thrombocytopenia, Anaemia</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Neutropenia, Leucopoenia</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:26.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:14.8pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:14.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Immune system disorders </p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:14.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:14.8pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Drug hypersensitivity</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:14.8pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:17.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:17.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Metabolism and nutrition
  disorders </p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:17.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:17.05pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Hypokalaemia</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:17.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:6.7pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:6.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Psychiatric disorders</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:6.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Insomnia</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:6.7pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:6.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:24.7pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:24.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Nervous system disorders</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:24.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Neuropathy peripheral,
  Headache </p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:24.7pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Dizziness, Dysgeusia, Memory impairment</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:24.7pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:35.95pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:35.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Eye disorders</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:35.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:35.95pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Dry eye, Conjunctivitis, Vision blurred, Lacrimation increased</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:35.95pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:8.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:8.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Cardiac disorders</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:8.05pt'>
  <p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:8.05pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Left ventricular dysfunction</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:8.05pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:3.5pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Vascular disorders</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Haemorrhage</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Hypertension</span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Respiratory, thoracic and
  mediastinal disorders</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Epistaxis, Cough, Dyspnoea</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Pneumonitis (ILD)</p>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Gastrointestinal disorders</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Stomatitis, Diarrhoea, Vomiting,
  Nausea, Constipation, Dry mouth, Abdominal pain</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Dyspepsia, Gingival bleeding</span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:13.05pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Hepatobiliary disorders</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Transaminases increased</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Blood alkaline phosphatase
  increased, blood bilirubin increased</span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:13.05pt'>
  <p class=MsoNormal style='margin-left:.55pt;text-indent:-.55pt;page-break-after:
  avoid'>Hepatotoxicity, Hepatic failure, Nodular regenerative hyperplasia,
  Portal hypertension</p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Skin and subcutaneous tissue
  disorders</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Rash, Pruritus, Alopecia, Nail
  disorder, Palmar-plantar erythrodysaesthesia syndrome, Urticaria</span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:18.2pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Musculoskeletal and connective
  tissue disorders</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Musculoskeletal pain, Arthralgia,
  Myalgia</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:18.2pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>&nbsp;</p>
  </td>
 </tr>
 <tr style='height:28.3pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:28.3pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>General disorders and
  administration site conditions </span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:28.3pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Fatigue, Pyrexia, Asthenia</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:28.3pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Peripheral oedema, Chills</span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:28.3pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Injection site extravasation</p>
  </td>
 </tr>
 <tr style='height:3.5pt'>
  <td width=181 nowrap valign=top style='width:135.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Injury, poisoning and procedural
  complications</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>
  </td>
  <td width=140 nowrap valign=top style='width:104.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=Default style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Infusion&#8209;related reactions </span></p>
  </td>
  <td width=127 nowrap valign=top style='width:95.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 4.25pt 0in 4.25pt;height:3.5pt'>
  <p class=MsoNormal style='margin-left:.5pt;text-indent:-.5pt;page-break-after:
  avoid'>Radiation pneumonitis</p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>Table 3
shows pooled data from the overall treatment period in the MBC studies (N=
1871; median number of cycles of trastuzumab emtansine was 10) and in KATHERINE
(N=740; median number of cycles was 14). </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><u>Description of selected
adverse reactions</u></p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Thrombocytopenia</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Thrombocytopenia or decreased
platelet counts were reported in 24.9% of patients in MBC clinical studies with
trastuzumab emtansine and was the most common adverse reaction leading to
treatment discontinuation (2.6%). Thrombocytopenia was reported in 28.5% of
patients in EBC clinical studies with trastuzumab emtansine and was the most
common reported adverse reaction for all grades and grades &#8805;&nbsp;3, as
well as the most common adverse reaction leading to treatment discontinuation (4.2%),
dose interruptions, and dose reductions. The majority of the patients had
Grade&nbsp;1 or&nbsp;2&nbsp;events (&#8805;&nbsp;50,000/mm<sup>3</sup>), with
the nadir occurring by day&nbsp;8 and generally improving to Grade&nbsp;0
or&nbsp;1 (&#8805;&nbsp;75,000/mm<sup>3</sup>) by the next scheduled dose. In
clinical studies, the incidence and severity of thrombocytopenia were higher in
Asian patients. Independent of race, the incidence of Grade&nbsp;3 or&nbsp;4
events (&lt;&nbsp;50,000/mm<sup>3</sup>) was 8.7% in patients with MBC treated
with trastuzumab emtansine and <span style='color:black'>5.7</span>% in
patients with EBC. For dose modifications for thrombocytopenia, see sections
4.2 and 4.4.&nbsp; </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>Haemorrhage</i></p>

<p class=MsoNormal>Haemorrhagic events were reported in 34.8% of patients in
MBC clinical trials with trastuzumab emtansine and <span style='color:black'>t</span>he
incidence of severe haemorrhagic events (Grade &#8805;3) occurred in 2.2%. Haemorrhagic
events were reported in 29% of patients with EBC and the incidence of severe
haemorrhagic events (Grade &#8805;3) was 0.4%, including one Grade 5 event. In
some of the observed cases the patients had thrombocytopenia, or were also
receiving anti-coagulant therapy or antiplatelet therapy; in others there were
no known additional risk factors. Cases of bleeding events with a fatal outcome
have been observed in both MBC and EBC.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Transaminases increased (AST/ALT)</i></p>

<p class=MsoNormal>Increase in serum transaminases (Grade&nbsp;1&#8209;4) has
been observed during treatment with trastuzumab emtansine in clinical studies
(see section&nbsp;4.4). Transaminase elevations were generally transient. A
cumulative effect of trastuzumab emtansine on transaminases has been observed,
and generally recovered when treatment was discontinued. Increased
transaminases were reported in 24.2% of patients in MBC clinical studies.
Grade&nbsp;3 or&nbsp;4 increased AST and ALT were reported in 4.2% and 2.7% of
patients with MBC respectively and usually occurred in the early treatment
cycles (1&#8209;6). Increased transaminases were reported in 32.4% of patients
with EBC. Grade 3 and 4 increased transaminases were reported in 1.5% of
patients with EBC. In general, the Grade&nbsp;&#8805;&nbsp;3 hepatic events
were not associated with poor clinical outcome; subsequent follow&#8209;up
values tended to show improvement to ranges allowing the patient to remain on
study and continue to receive study treatment at the same or reduced dose. No
relationship was observed between trastuzumab emtansine exposure (AUC),
trastuzumab emtansine maximum serum concentration (C<sub>max</sub>), total
trastuzumab exposure (AUC), or C<sub>max</sub> of DM1 and increases in
transaminase. For dose modifications in the event of increased transaminases,
see sections 4.2 and 4.4. </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>Left ventricular dysfunction</i></p>

<p class=MsoNormal>Left ventricular dysfunction was reported in 2.2% of
patients in MBC clinical studies with trastuzumab emtansine. The majority of
events were asymptomatic Grade&nbsp;1 or&nbsp;2 decrease in LVEF. Grade&nbsp;3
or&nbsp;4 events were reported in 0.4% of patients with MBC. Left ventricular
dysfunction occurred in 3.0% of patients with EBC, with Grade 3 or 4 in 0.5% of
patients. Additional LVEF monitoring is recommended for patients with
LVEF&nbsp;&#8804; 45% (See Table&nbsp;5 in section 4.2 for specific dose
modifications). </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Peripheral neuropathy</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Peripheral neuropathy, mainly
as Grade 1 and predominantly sensory, was reported in clinical trials of trastuzumab
emtansine. In patients with MBC, the overall incidence of peripheral neuropathy
was 29.0% and 8.6% for Grade &#8805; 2. In patients with EBC, the overall
incidence was 32.3% and 10.3% for Grade &#8805; 2. </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Infusion&#8209;related
reactions</i></p>

<p class=MsoNormal style='page-break-after:avoid'>Infusion&#8209;related
reactions are characterised by one or more of the following symptoms: flushing,
chills, pyrexia, dyspnoea, hypotension, wheezing, bronchospasm and tachycardia.
Infusion&#8209;related reactions were reported in 4.0% of patients in MBC clinical
studies with trastuzumab emtansine, with six Grade&nbsp;3 and no Grade&nbsp;4
events reported. Infusion-related reactions were reported in 1.6% of patients
with EBC, with no Grade 3 or 4 events reported. Infusion&#8209;related
reactions resolved over the course of several hours to a day after the infusion
was terminated. No dose relationship was observed in clinical studies. For dose
modifications in the event of infusion&#8209;related reactions, see sections
4.2 and 4.4. </p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>Hypersensitivity reactions</i></p>

<p class=MsoNormal>Hypersensitivity was reported in 2.6% of patients in MBC clinical
studies with trastuzumab emtansine, with one Grade&nbsp;3 and one Grade 4
events reported. Hypersensitivity was reported in 2.7% of patients with EBC,
with Grade 3 or 4 in 0.4% of patients. Overall, the majority of
hypersensitivity reactions were mild or moderate in severity and resolved upon
treatment. For dose modifications in the event of hypersensitivity reactions,
see sections 4.2 and 4.4. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Immunogenicity</i></p>

<p class=MsoNormal>As with all therapeutic proteins, there is the potential for
an immune response to trastuzumab emtansine. A total of 1243 patients from
seven clinical studies were tested at multiple time points for anti-drug
antibody (ADA) responses to trastuzumab emtansine. Following trastuzumab
emtansine dosing, 5.1% (63/1243) of patients tested positive for anti-trastuzumab
emtansine antibodies at one or more post-dose time points. In the Phase I and
Phase II studies, 6.4% (24/376) of patients tested positive for anti- trastuzumab
emtansine antibodies. In the EMILIA study (TDM4370g/BO21977), 5.2% (24/466) of
patients tested positive for anti-trastuzumab emtansine antibodies, of which 13
were also positive for neutralizing antibodies. In the KATHERINE (BO27938)
study, 3.7% (15/401) of patients tested positive for anti-trastuzumab emtansine
antibodies, of which 5 were also positive for neutralizing antibodies. Due to
the low incidence of ADA, conclusions cannot be made on the impact of anti- trastuzumab
emtansine antibodies on the pharmacokinetics, safety, and efficacy of trastuzumab
emtansine. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><i>Extravasation</i></p>

<p class=MsoNormal>Reactions secondary to extravasation have been observed in
clinical studies with trastuzumab emtansine. These reactions were usually mild
or moderate and comprised erythema, tenderness, skin irritation, pain, or
swelling at the infusion site. These reactions have been observed more
frequently within 24&nbsp;hours of infusion. Specific treatment for trastuzumab
emtansine extravasation is unknown at this time. </p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal><u>Laboratory abnormalities</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Tables&nbsp;4 and 5 displays laboratory abnormalities
observed in patients treated with trastuzumab emtansine in clinical study
TDM4370g/BO21977/EMILIA and study BO27938/KATHERINE.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:49.65pt;text-indent:-49.65pt;page-break-after:
avoid'><b>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp; Laboratory abnormalities
observed in patients treated with trastuzumab emtansine in study
TDM4370g/BO21977/EMILIA</b></p>

<p class=MsoNormal style='margin-left:49.65pt;text-indent:-49.65pt;page-break-after:
avoid'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=577
 style='width:432.75pt;margin-left:4.65pt;border-collapse:collapse'>
 <tr style='height:15.0pt'>
  <td width=259 nowrap rowspan=2 valign=bottom style='width:194.25pt;
  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Parameter</span></b></p>
  </td>
  <td width=318 nowrap colspan=3 valign=bottom style='width:238.5pt;border:
  solid windowtext 1.0pt;border-left:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Trastuzumab emtansine (N=490)</span></b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>All Grades&nbsp;(%)</span></b></p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Grade&nbsp;3 (%)</span></b></p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Grade&nbsp;4 (%)</span></b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=577 nowrap colspan=4 valign=bottom style='width:432.75pt;
  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Hepatic</b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased bilirubin</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>21</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;&nbsp;1</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased AST</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>98</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>8</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;&nbsp;1</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased ALT</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>82</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>5</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;&nbsp;1</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=577 nowrap colspan=4 valign=bottom style='width:432.75pt;
  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Haematologic</b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased platelet count</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>85</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>14</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>3</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased haemoglobin</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>63</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>5</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>1</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased neutrophils</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>41</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>4</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;&nbsp;1</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=577 nowrap colspan=4 valign=bottom style='width:432.75pt;
  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Potassium</b></p>
  </td>
 </tr>
 <tr style='height:2.9pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased potassium</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>35</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>3</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt; 1</p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laboratory
abnormalities observed in patients treated with trastuzumab emtansine in study BO27938/KATHERINE</b></p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=577
 style='width:432.75pt;margin-left:4.65pt;border-collapse:collapse'>
 <tr style='height:15.0pt'>
  <td width=259 nowrap rowspan=2 valign=bottom style='width:194.25pt;
  border:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Parameter</span></b></p>
  </td>
  <td width=318 nowrap colspan=3 style='width:238.5pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=DE style='font-size:
  11.0pt;color:windowtext'>Trastuzumab emtansine (N=740)</span></b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>All Grade %</span></b></p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Grade&nbsp;3 (%)</span></b></p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=Default align=center style='margin-left:-.05pt;text-align:center;
  text-indent:.05pt;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt;color:windowtext'>Grade&nbsp;4 (%)</span></b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=577 nowrap colspan=4 valign=bottom style='width:432.75pt;
  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Hepatic</b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased bilirubin</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>11</p>
  </td>
  <td width=114 nowrap style='width:85.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased AST</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>79</p>
  </td>
  <td width=114 nowrap style='width:85.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;1</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Increased ALT</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>55</p>
  </td>
  <td width=114 nowrap style='width:85.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;1</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=577 nowrap colspan=4 valign=bottom style='width:432.75pt;
  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Haematologic</b></p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased platelet count</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>51</p>
  </td>
  <td width=114 nowrap style='width:85.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>4</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>2</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased haemoglobin</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>31</p>
  </td>
  <td width=114 nowrap style='width:85.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>1</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=259 nowrap style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased neutrophils</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>24</p>
  </td>
  <td width=114 nowrap style='width:85.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>1</p>
  </td>
  <td width=102 nowrap style='width:76.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:15.0pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>0</p>
  </td>
 </tr>
 <tr style='height:15.0pt'>
  <td width=577 nowrap colspan=4 valign=bottom style='width:432.75pt;
  border:solid windowtext 1.0pt;border-top:none;padding:0in 5.4pt 0in 5.4pt;
  height:15.0pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b>Potassium</b></p>
  </td>
 </tr>
 <tr style='height:2.9pt'>
  <td width=259 nowrap valign=bottom style='width:194.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal style='page-break-after:avoid'>Decreased potassium</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>26</p>
  </td>
  <td width=114 nowrap valign=bottom style='width:85.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>2</p>
  </td>
  <td width=102 nowrap valign=bottom style='width:76.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:2.9pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'>&lt;1</p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Reporting of suspected adverse reactions</u></p>

<p class=MsoNormal>Reporting suspected adverse reactions after authorisation of
the medicinal product is important. It allows continued monitoring of the
benefit/risk balance of the medicinal product. Healthcare professionals are
asked to report any suspected adverse reactions via <span style='background:
lightgrey'>the national reporting system listed in </span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='background:lightgrey'>.</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>There is no known antidote for trastuzumab emtansine overdose.
In case of overdose, the patient should be closely monitored for signs or
symptoms of adverse reactions and appropriate symptomatic treatment instituted.
Cases of overdose have been reported with trastuzumab emtansine treatment, most
associated with thrombocytopenia, and there was one death. In the fatal case,
the patient incorrectly received trastuzumab emtansine 6&nbsp;mg/kg and died
approximately 3&nbsp;weeks following the overdose; a causal relationship to
trastuzumab emtansine was not established.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b>5.1 &nbsp;&nbsp;&nbsp; Pharmacodynamic properties</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Pharmacotherapeutic group: Antineoplastic agents, other
antineoplastic agents, monoclonal</p>

<p class=MsoNormal>antibodies, ATC code: L01XC14</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Mechanism of action</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u><span style='text-decoration:
 none'>&nbsp;</span></u></p>

<p class=MsoNormal style='page-break-after:avoid'>Kadcyla, trastuzumab
emtansine, is a HER2&#8209;targeted antibody&#8209;drug conjugate which
contains the humanised anti&#8209;HER2 IgG1, trastuzumab, covalently linked to
the microtubule inhibitor DM1 (a maytansine derivative) via the stable
thioether linker MCC&nbsp;(4&#8209;[N&#8209;maleimidomethyl]&nbsp;cyclohexane&#8209;1&#8209;carboxylate).
Emtansine refers to the MCC&#8209;DM1 complex. An average of 3.5&nbsp;DM1
molecules are conjugated to each molecule of trastuzumab. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Conjugation of DM1 to trastuzumab confers selectivity of the
cytotoxic agent for HER2&#8209;overexpressing tumour cells, thereby increasing
intracellular delivery of DM1 directly to malignant cells. Upon binding to
HER2, trastuzumab emtansine undergoes receptor&#8209;mediated internalization
and subsequent lysosomal degradation, resulting in release of DM1&#8209;containing
cytotoxic catabolites (primarily lysine&#8209;MCC&#8209;DM1).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Trastuzumab emtansine has the mechanisms of action of both
trastuzumab and DM1: </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Trastuzumab
emtansine, like trastuzumab, binds to domain&nbsp;IV of the HER2 extracellular
domain (ECD), as well as to Fc&#947; receptors and complement&nbsp;C1q. In addition,
trastuzumab emtansine, like trastuzumab, inhibits shedding of the HER2 ECD,
inhibits signalling through the phosphatidylinositol&nbsp;3&#8209;kinase (PI3&#8209;K)
pathway, and mediates antibody&#8209;dependent cell&#8209;mediated cytotoxicity
(ADCC) in human breast cancer cells that overexpress HER2.&nbsp; </p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; DM1, the
cytotoxic component of trastuzumab emtansine, binds to tubulin. By inhibiting
tubulin polymerization, both DM1 and trastuzumab emtansine cause cells to
arrest in the G2/M phase of the cell cycle, ultimately leading to apoptotic
cell death. Results from <i>in vitro</i> cytotoxicity assays show that DM1 is
20&#8209;200 times more potent than taxanes and vinca alkaloids. </p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; The
MCC&nbsp;linker is designed to limit systemic release and increase targeted
delivery of DM1, as demonstrated by detection of very low levels of free DM1 in
plasma. </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Clinical efficacy </u></p>

<p class=MsoNormal style='page-break-after:avoid'><b><u><span style='text-decoration:
 none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><i><u>Early
Breast Cancer</u></i></p>

<p class=Paragraph style='margin-bottom:0in;line-height:normal'><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><u><span lang=EN-GB>BO27938
(KATHERINE) </span></u></i></p>

<p class=MsoNormal style='text-autospace:none'><i><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></i></p>

<p class=MsoNormal style='text-autospace:none'>BO27938 (KATHERINE)&nbsp;was a
randomized, multicenter, open-label trial of 1486 patients with HER2-positive,
early breast cancer with residual invasive tumor&nbsp;<span lang=EN-GB>(patients
who had not achieved pathological complete response (pCR))</span>&nbsp;in the
breast and/or axillary lymph nodes following completion of preoperative
systemic therapy that included chemotherapy and HER2-targeted therapy. Patients
may have received more than one HER2-targeted therapy. Patients received
radiotherapy and/or hormonal therapy concurrent with study treatment as per
local guidelines. Breast tumor samples were required to show HER2
overexpression defined as 3+ IHC or ISH amplification ratio &#8805; 2.0
determined at a central laboratory. Patients were randomized (1:1) to receive
trastuzumab or trastuzumab emtansine. Randomization was stratified by clinical
stage at presentation (operable vs. inoperable), hormone receptor status, preoperative
HER2-directed therapy (trastuzumab, trastuzumab plus additional HER2-directed
agent[s]), and pathological nodal status evaluated after preoperative therapy.</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=TextTi12 align=left style='margin-bottom:0in;text-align:left'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Trastuzumab
emtansine was given intravenously at 3.6 mg/kg on Day 1 of a 21-day
cycle.&nbsp; Trastuzumab was given intravenously at 6 mg/kg on Day 1 of a
21-day cycle. Patients were treated with trastuzumab emtansine or trastuzumab
for a total of 14 cycles unless there was recurrence of disease, withdrawal of
consent, or unacceptable toxicity, whichever occurred first. Patients who
discontinued trastuzumab emtansine could complete the duration of their
intended study treatment up to 14 cycles of HER2-directed therapy with
trastuzumab if appropriate based on toxicity considerations and investigator
discretion.</span></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>The primary efficacy endpoint of the study
was Invasive Disease-Free Survival (IDFS). IDFS was defined as the time from
the date of randomization to first occurrence of ipsilateral invasive breast
tumor recurrence, ipsilateral local or regional invasive breast cancer
recurrence, distant recurrence, contralateral invasive breast cancer, or death
from any cause. Additional endpoints included IDFS including second primary
non-breast cancer, disease-free survival (DFS), overall survival (OS), and
distant recurrence-free interval (DRFI).</span></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>Patient demographics and baseline tumor
characteristics were balanced between treatment arms.&nbsp; The median age was
approximately 49 years (range 23-80 years), 72.8% were White, 8.7% were Asian
and 2.7% were Black or African American.&nbsp; All but 5 patients were women; 3
men were included in the trastuzumab arm and 2 in the trastuzumab emtansine arm.
22.5 percent of patients were enrolled in North America, 54.2% in Europe and
23.3% throughout the rest of the world.&nbsp; Tumor prognostic characteristics
including hormone receptor status (positive: 72.3%, negative: 27.7%), clinical
stage at presentation (inoperable: 25.3%, operable: 74.8%) and pathological
nodal status after preoperative therapy (node positive: 46.4%, node negative or
not evaluated: 53.6%) were similar in the study arms.&nbsp;&nbsp; </span></p>

<p class=TextTi12 style='margin-bottom:0in'><span style='font-size:11.0pt;
font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>The majority of
the patients (76.9%) had received an anthracycline-containing neoadjuvant
chemotherapy regimen.19.5% percent of patients received another HER2-targeted
agent in addition to trastuzumab as a component of neoadjuvant therapy; 93.8%
of these patients received pertuzumab. All of the patients had received taxanes
as part of neoadjuvant chemotherapy.</span></p>

<p class=Paragraph style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=Paragraph style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;color:black;
background:white'>A clinically meaningful and statistically significant
improvement in IDFS was observed in patients who received trastuzumab emtansine
compared with trastuzumab (HR = 0.50, 95% CI [0.39, 0.64], p &lt;0.0001.
Estimates of 3 years IDFS rates were 88.3% vs. 77.0%&nbsp;in trastuzumab
emtansine vs. trastuzumab&nbsp;arms, respectively. See Table 6 and Figure 1.</span></p>

<p class=Paragraph style='margin-bottom:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;background:white'>&nbsp;</span></p>

<p class=TableTitle style='margin-top:0in;line-height:normal'><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Summary of </span><span
lang=EN-CARRIBEAN style='font-size:11.0pt;font-family:"Times New Roman",serif'>e</span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>fficacy from </span><span
lang=EN-CARRIBEAN style='font-size:11.0pt;font-family:"Times New Roman",serif'>s</span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>tudy </span><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>BO27938 (<span
style='letter-spacing:.05pt'>KATHERINE</span>) </span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=584
 style='width:437.7pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
   2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
   line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=150 valign=bottom style='width:112.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span style='font-size:10.0pt'>Trastuzumab </span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span style='font-size:10.0pt'>N = 743</span></b></p>
   </td>
   <td width=142 valign=bottom style='width:106.35pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt'>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span style='font-size:10.0pt'>Trastuzumab
   Emtansine</span></b></p>
   <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
   margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
   page-break-after:avoid'><b><span style='font-size:10.0pt'>N = 743</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><b><i><span style='font-size:10.0pt'>Primary
  Endpoint</span></i></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b><i><span style='font-size:10.0pt'>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><b><span style='font-size:10.0pt'>Invasive
  Disease-Free Survival (IDFS)<sup> &nbsp;</sup></span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>Number
  (%) of patients with event </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>165 (22.2%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>91 (12.2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>HR
  [95% CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>0.50 [0.39, 0.64]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>p-value
  (Log-Rank test, unstratified)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>3
  year event-free rate<sup>2</sup>,% [95% CI] </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>77.02 [73.78, 80.26]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>88.27 [85.81, 90.72]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><b><i><span style='font-size:10.0pt'>Secondary
  Endpoints<sup>1</sup></span></i></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b><i><span style='font-size:10.0pt'>&nbsp;</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:6.1pt'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:6.1pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><b><span style='font-size:10.0pt'>Overall
  Survival (OS)</span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:
  6.1pt'>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:8.6pt;page-break-after:avoid;punctuation-wrap:simple'><span
  style='font-size:8.0pt;font-family:"Courier New"'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>Number
  (%) of patients with event</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt;
  height:10.9pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>56 (7.5%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>42 (5.7%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>HR
  [95% CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:
  10.9pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>&nbsp;0.70 [0.47,
  1.05]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>p-value
  (Log-Rank test, unstratified)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:
  10.9pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>0.0848</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.9pt'>
  <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>5
  year survival rate<sup>2</sup>,% [95% CI]</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>86.8 [80.95, 92.63]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:10.9pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:11.3pt;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>92.1 [89.44, 94.74]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b><span
  style='font-size:10.0pt'>IDFS</span></b> <b><span style='font-size:10.0pt'>including
  second primary non-breast cancer<sup>3</sup></span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:8.0pt;font-family:"CourierStd",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>Number
  (%) of patients with event </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>167 (22.5%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>95 (12.8%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'><span
  style='font-size:10.0pt'>HR [95% CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=top style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>0.51 [0.40, 0.66]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>p-value
  (Log-Rank test, unstratified)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>3
  year event-free rate<sup>2</sup>,% [95% CI] </span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>76.9 [73.65, 80.14]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>87.7 [85.18, 90.18]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><b><span style='font-size:10.0pt'>Disease-Free
  Survival (DFS)<sup>3</sup> </span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b><span style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>Number
  (%) of patients with event</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>167 (22.5%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>98 (13.2%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>HR
  [95% CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>&nbsp;0.53 [0.41,
  0.68]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>p-value
  (Log-Rank test, unstratified)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>&lt;0.0001</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>3
  year event-free rate<sup>2</sup>,% [95% CI]</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>76.9 [73.65, 80.14]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>87.41 [84.88, 89.93]</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><b><span style='font-size:10.0pt'>Distant
  recurrence-free interval (DRFI)<sup>3</sup></span></b></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:8.0pt;font-family:"CourierStd",serif'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>Number
  (%) of patients with event</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>121 (16.3%)</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border:none;border-right:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>78 (10.5%)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>HR
  [95% CI]</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>0.60 [0.45, 0.79]</span><sup><span
  style='font-size:9.0pt'> </span></sup></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=bottom style='width:218.85pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:10.65pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>p-value
  (Log-Rank test, unstratified)</span></p>
  </td>
  <td width=292 colspan=2 valign=bottom style='width:218.85pt;border:none;
  border-right:solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>0.0003</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=292 valign=top style='width:218.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-align:justify;text-justify:inter-ideograph;
  line-height:12.0pt;page-break-after:avoid'><span style='font-size:10.0pt'>3
  year event-free rate<sup>2</sup>,% [95% CI]</span></p>
  </td>
  <td width=150 valign=bottom style='width:112.5pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>83.0 [80.10, 85.92 ]</span></p>
  </td>
  <td width=142 valign=bottom style='width:106.35pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><span style='font-size:10.0pt'>89.7 [87.37, 92.01 ]</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b><span style='font-size:10.0pt'>Data from first interim
analysis 25 July 2018</span></b></p>

<p class=MsoNormal><b><span style='font-size:10.0pt'>Key to abbreviations
(Table6): </span></b><span style='font-size:10.0pt'>HR: Hazard Ratio; CI:
Confidence Intervals, </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span style='font-size:10.0pt'>1. Hierarchical testing
applied for IDFS and OS </span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span style='font-size:10.0pt'>2. 3-year event-free rate
and 5-year survival rate derived from Kaplan-Meier estimates</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'><span style='font-size:10.0pt'>3. These secondary
endpoints were not adjusted for multiplicity</span><span style='font-size:10.0pt'>
</span></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
text-autospace:none'>&nbsp;</p>

<p class=FigureHolder style='text-align:justify;text-justify:inter-ideograph'><b><span
style='font-size:11.0pt;font-family:"Times New Roman",serif'>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier
Curve of Invasive Disease-Free Survival in KATHERINE</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><img border=0 width=605
height=406 id="Picture 3"
src="Kadcyla%20II-45%20EN%20PIclean_files/image001.gif"></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal>In KATHERINE, consistent treatment benefit of trastuzumab
emtansine for IDFS was seen in all the pre&#8209;specified subgroups evaluated,
supporting the overall result. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;page-break-after:
avoid'><i><u>Metastatic Breast Cancer</u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><i>&nbsp;</i></p>

<p class=MsoNormal style='page-break-after:avoid'><i><u>TDM4370g/BO21977(EMILIA)</u></i></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'>A Phase&nbsp;III, randomised,
multicentre, international, open&#8209;label clinical study was conducted in
patients with HER2&#8209;positive unresectable locally advanced breast cancer
(LABC) or MBC who had received prior taxane and trastuzumab&#8209;based
therapy, including patients who received prior therapy with trastuzumab and a
taxane in the adjuvant setting and who relapsed during or within six months of
completing adjuvant therapy. Only patients with Eastern Cooperative Oncology
Group (ECOG) Performance Status 0 or 1 were eligible.<i>&nbsp;</i>Prior to
enrolment, breast tumour samples were required to be centrally confirmed for
HER2&#8209;positive status defined as a score of 3&nbsp;+ by IHC or gene
amplification by ISH. Baseline patient and tumour characteristics were well
balanced between treatment groups. Patients with treated brain metastases were
eligible for enrollment if they did not require therapy to control symptoms.
For patients randomised to trastuzumab emtansine, the median age was 53&nbsp;years,
most patients were female (99.8%), the majority were Caucasian (72%), and 57%
had oestrogen&#8209;receptor and/or progesterone&#8209;receptor positive
disease. The study compared the safety and efficacy of trastuzumab emtansine
with that of lapatinib plus capecitabine. A total of 991&nbsp;patients were
randomised to trastuzumab emtansine or lapatinib plus capecitabine as follows:</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Trastuzumab
emtansine arm: trastuzumab emtansine 3.6&nbsp;mg/kg intravenously over 30&#8209;90&nbsp;minutes
on Day&nbsp;1 of a 21&#8209;day cycle </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Control
arm (lapatinib plus capecitabine): lapatinib 1250&nbsp;mg/day orally once per
day of a 21&#8209;day cycle plus capecitabine 1000&nbsp;mg/m<sup>2</sup> orally
twice daily on Days&nbsp;1&#8209;14 of a 21&#8209;day cycle</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>The co&#8209;primary efficacy
endpoints of the study were progression&#8209;free survival (PFS) as assessed
by an independent review committee (IRC) and overall survival (OS)
(see&nbsp;Table&nbsp;7&nbsp;and&nbsp;Figures 2&nbsp;to&nbsp;3). </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal>Time to symptom&nbsp;progression, as defined by a 5&#8209;point
decrease in the score derived from the Trials Outcome Index&#8209;Breast (TOI&#8209;B)
subscale of the Functional Assessment of Cancer Therapy&#8209;Breast Quality of
Life (FACT&#8209;B&nbsp;QoL) questionnaire was also assessed during the
clinical study. A change of 5&nbsp;points in the TOI&#8209;B is considered
clinically significant. Kadcyla delayed patient-reported time to symptom progression
for 7.1 months compared with 4.6 months for the control arm (Hazard Ratio 0.796
(0.667, 0.951); p-value 0.0121). The data are from an open-label study and no
firm conclusions can be drawn.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Table&nbsp;7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary
of efficacy from study TDM4370g/BO21977 (EMILIA) </b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=586
 style='margin-left:2.85pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:14.5pt'>
   <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
   padding:0in 2.85pt 0in 2.85pt;height:14.5pt'>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></b></p>
   </td>
   <td width=186 valign=bottom style='width:139.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt'>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Lapatinib
   + Capecitabine</span></b></p>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>n&nbsp;=&nbsp;496</span></b></p>
   </td>
   <td width=148 valign=bottom style='width:110.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 2.85pt 0in 2.85pt;height:14.5pt'>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Trastuzumab
   emtansine</span></b></p>
   <p class=Default align=center style='text-align:center;page-break-after:
   avoid'><b><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>n&nbsp;=&nbsp;495</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=586 colspan=3 style='width:439.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>Primary
  endpoints</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>IRC-assessed
  progression-free survival (PFS)</b></p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Number
  (%) of patients with event </p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>304 (61.3%)</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>265 (53.5%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Median
  duration of PFS (months) </p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>6.4</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>9.6</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Hazard
  ratio (stratified*)</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>0.650</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>95% CI
  for Hazard ratio</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>(0.549, 0.771)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>p-value
  (Log-rank test, stratified*)</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>&lt;&nbsp;0.0001</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>Overall
  Survival (OS)** </b></p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Number
  (%) of patients who died </p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>182 (36.7%)</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>149 (30.1%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Median
  duration of survival (months)</p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>25.1</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>30.9</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Hazard
  ratio (stratified*)</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>0.682</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>95% CI
  for Hazard ratio</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>(0.548, 0.849)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:4.0pt'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt;height:4.0pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>p-value
  (Log-rank test*)</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt;height:4.0pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>0.0006</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=586 colspan=3 style='width:439.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>Key
  secondary endpoints</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>Investigator-assessed
  PFS</b></p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Number
  (%) of patients with event </p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>335 (67.5%)</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>287 (58.0%)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Median
  duration of PFS (months) </p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>5.8</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>9.4</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>Hazard
  ratio (95% CI)</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>0.658 (0.560, 0.774)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;line-height:12.0pt;page-break-after:avoid'>p-value
  (Log-rank test*)</p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>&lt;0.0001</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>Objective
  response rate (ORR)</b></p>
  </td>
  <td width=334 colspan=2 valign=bottom style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b><i>&nbsp;&nbsp;&nbsp;
  </i></b>Patients with measurable disease</p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>389</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>397</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=252 valign=bottom style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.35pt;line-height:12.0pt;page-break-after:avoid'>Number
  of patients with OR (%)</p>
  </td>
  <td width=186 valign=bottom style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>120 (30.8%)</p>
  </td>
  <td width=148 valign=bottom style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 2.85pt 0in 2.85pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>173 (43.6%)</p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:
  avoid'>Difference (95% CI)</p>
  </td>
  <td width=334 colspan=2 valign=top style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>12.7% (6.0, 19.4)</p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:
  avoid'>p-value (Mantel-Haenszel chi-squared test*)</p>
  </td>
  <td width=334 colspan=2 valign=top style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>0.0002</p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;line-height:12.0pt;page-break-after:avoid'><b>Duration
  of objective response (months)</b></p>
  </td>
  <td width=334 colspan=2 valign=top style='width:250.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:0in;text-indent:8.8pt;line-height:12.0pt;page-break-after:
  avoid'>Number of patients with OR</p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>120</p>
  </td>
  <td width=148 valign=top style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>173</p>
  </td>
 </tr>
 <tr>
  <td width=252 valign=top style='width:189.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:2.5pt;margin-right:0in;margin-bottom:
  2.5pt;margin-left:11.3pt;text-indent:-2.5pt;line-height:12.0pt;page-break-after:
  avoid'>Median 95% CI</p>
  </td>
  <td width=186 valign=top style='width:139.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>6.5 (5.5, 7.2) </p>
  </td>
  <td width=148 valign=top style='width:110.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:2.5pt;margin-right:0in;
  margin-bottom:2.5pt;margin-left:0in;text-align:center;line-height:12.0pt;
  page-break-after:avoid'>12.6 (8.4, 20.8)</p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:11.35pt;page-break-after:avoid'>OS:
overall survival; PFS: progression-free survival; ORR: objective response rate;
OR: objective response; IRC: independent review committee; HR: hazard ratios;
CI: confidence interval</p>

<p class=MsoNormal style='margin-left:11.35pt;text-indent:-7.1pt'>* Stratified
by: world region (United States, Western Europe, other), number of prior
chemotherapeutic regimens for locally advanced or metastatic disease (0-1 <i>vs.</i>
&gt;&nbsp;1), and visceral <i>vs.</i> non-visceral disease.</p>

<p class=MsoNormal style='margin-left:11.35pt;text-indent:-11.35pt'>** The
interim analysis for OS was conducted when 331 events were observed. Since the
efficacy boundary was crossed at this analysis, this is considered the
definitive analysis.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>A treatment benefit was seen in the subgroup of patients who
had relapsed within 6 months of completing adjuvant treatment and had not
received any prior systemic anti-cancer therapy in the metastatic setting
(n=118); hazard ratios for PFS and OS were 0.51 (95% CI: 0.30, 0.85) and 0.61
(95% CI: 0.32, 1.16), respectively. The median PFS and OS for the trastuzumab
emtansine group were 10.8 months and not reached,&nbsp;respectively, compared
with 5.7 months and 27.9 months, respectively, for the lapatinib plus capecitabine
group. </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-meier
curve of IRC-assessed progression-free survival</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><img border=0 width=605
height=385 id="Picture 1"
src="Kadcyla%20II-45%20EN%20PIclean_files/image002.gif"></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Figure&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-meier
curve of overall survival</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><img border=0 width=604
height=387 id="Picture 2"
src="Kadcyla%20II-45%20EN%20PIclean_files/image003.gif"></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal>In study TDM4370g/BO21977, consistent treatment benefit of
trastuzumab emtansine was seen in the majority of pre&#8209;specified subgroups
evaluated, supporting the robustness of the overall result. In the subgroup of
patients with hormone receptor-negative disease (n=426), the hazard ratios for
PFS and OS were 0.56 (95% CI: 0.44, 0.72) and 0.75 (95% CI: 0.54, 1.03),
respectively.&nbsp; In the subgroup of patients with hormone receptor-positive
disease (n=545), the hazard ratios for PFS and OS were 0.72 (95% CI: 0.58,
0.91) and 0.62 (95% CI: 0.46, 0.85), respectively.&nbsp; </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In the subgroup of patients with non-measurable disease
(n=205), based on IRC assessments, the hazard ratios for PFS and OS were 0.91
(95% CI: 0.59, 1.42) and 0.96 (95% CI: 0.54, 1.68), respectively. In patients
&#8805; 65 years old (n=138 across both treatment arms) the hazard ratios for
progression-free survival (PFS) and Overall Survival (OS) were 1.06 (95% CI:
0.68, 1.66) and 1.05 (95% CI: 0.58, 1.91), respectively. In patients 65 to
74&nbsp;years old (n=113), based on IRC assessments, the hazard ratios for PFS
and OS were 0.88 (95% CI: 0.53, 1.45) and 0.74 (95% CI: 0.37, 1.47),
respectively.&nbsp; For patients 75&nbsp;years or above, based on IRC
assessments, the hazard ratios for PFS and OS were 3.51 (95% CI: 1.22, 10.13)
and 3.45 (95% CI: 0.94, 12.65), respectively. The subgroup of patients
75&nbsp;years or above did not demonstrate a benefit for PFS or OS, but was too
small (n=25) to draw any definitive conclusions. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In the descriptive follow-up overall survival analysis, the
hazard ratio was 0.75 (95% CI 0.64, 0.88). The median duration of overall
survival was 29.9 months in the trastuzumab emtansine arm compared with 25.9
months in the lapatinib plus capecitabine arm. At the time of the descriptive
follow-up overall survival analysis, a total of 27.4% of the patients had
crossed over from the lapatinib plus capecitabine arm to the trastuzumab
emtansine arm. In a sensitivity analysis censoring patients at the time of
cross-over, the hazard ratio was 0.69 (95% CI 0.59, 0.82). The results of this
descriptive follow-up analysis are consistent with the confirmatory OS analysis.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><i><u>TDM4450g</u></i></p>

<p class=MsoNormal>A randomised, multicentre, open&#8209;label phase&nbsp;II
study evaluated the effects of trastuzumab emtansine versus trastuzumab plus
docetaxel in patients with HER2&#8209;positive MBC who had not received prior
chemotherapy for metastatic disease. Patients were randomised to receive
trastuzumab emtansine 3.6&nbsp;mg/kg intravenously every 3 weeks
(n&nbsp;=&nbsp;67) or trastuzumab&nbsp;8&nbsp;mg/kg intravenous loading dose
followed by 6&nbsp;mg/kg intravenously every 3&nbsp;weeks plus docetaxel 75&#8209;100&nbsp;mg/m<sup>2</sup>
intravenously every 3&nbsp;weeks (n&nbsp;=&nbsp;70).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The primary endpoint was investigator assessed Progression&#8209;Free
Survival (PFS). The median PFS was 9.2&nbsp;months in the trastuzumab plus
docetaxel arm and 14.2&nbsp;months in the trastuzumab emtansine arm (hazard
ratio, 0.59; p&nbsp;=&nbsp;0.035), with a median follow&#8209;up of
approximately 14&nbsp;months in both arms. The objective response rate (ORR)
was 58.0% with trastuzumab plus docetaxel and 64.2% with trastuzumab emtansine.
The median duration of response was not reached with trastuzumab emtansine <i>vs.</i>
9.5&nbsp;months in the control arm.</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><i><u>TDM4374g </u></i></p>

<p class=MsoNormal style='page-break-after:avoid'>A Phase&nbsp;II, single&#8209;arm,
open&#8209;label study evaluated the effects of trastuzumab emtansine in
patients with HER2&#8209;positive incurable, LABC or MBC. All patients were
previously treated with HER2&#8209;directed therapies (trastuzumab and
lapatinib), and chemotherapy (anthracycline, taxane, and capecitabine) in the
neoadjuvant, adjuvant, locally advanced, or metastatic setting. The median
number of anti&#8209;cancer agents that patients had received in any setting
was 8.5 (range, 5&#8209;19) and in the metastatic setting was 7.0 (range, 3&#8209;17),
including all agents intended for the treatment of breast cancer. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Patients (n&nbsp;=&nbsp;110) received 3.6&nbsp;mg/kg of
trastuzumab emtansine intravenously every 3&nbsp;weeks until disease
progression or unacceptable toxicity. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The key efficacy analyses were ORR based on independent
radiologic review and duration of objective response. The ORR was 32.7% (95%
CI: 24.1,&nbsp;42.1), n&nbsp;=&nbsp;36 responders, by both IRC and investigator
review. The median duration of response by IRC was not reached (95% CI,
4.6&nbsp;months to not estimable).</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u>Paediatric population</u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>The European Medicines Agency has waived the obligation to
submit the results of studies with trastuzumab emtansine in all subsets of the
paediatric population in breast cancer (see section&nbsp;4.2 for information on
paediatric use).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'>The population pharmacokinetic analysis suggested no
difference in trastuzumab emtansine exposure based on disease status (adjuvant
vs. metastatic setting).</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u>Absorption </u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'>Trastuzumab emtansine is administered intravenously.
There have been no studies performed with other routes of administration. </p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u>Distribution </u></p>

<p class=MsoNormal>Patients in Study TDM4370g/BO21977 and Study BO29738 who
received 3.6&nbsp;mg/kg of trastuzumab emtansine intravenously every
3&nbsp;weeks had a mean Cycle 1 maximum serum concentration (C<sub>max</sub>)
of trastuzumab emtansine of 83.4&nbsp;(&plusmn;&nbsp;16.5)&nbsp;<span
style='font-family:Symbol'>m</span>g/mL and 72.6 (&plusmn; 24.3) <span
style='font-family:Symbol'>m</span>g/mL, respectively. Based on population PK
analysis, following intravenous administration, the central volume of
distribution of trastuzumab emtansine was (3.13&nbsp;L) and approximated that
of plasma volume. </p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><i>&nbsp;</i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u><span
lang=DE>Biotransformation (trastuzumab emtansine and DM1)</span></u></p>

<p class=MsoNormal>Trastuzumab emtansine is expected to undergo deconjugation
and catabolism by means of proteolysis in cellular lysosomes. </p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal><i>In vitro</i> metabolism studies in human liver microsomes
suggest that DM1, a small molecule component of trastuzumab emtansine, is
metabolised mainly by CYP3A4 and to a lesser extent by CYP3A5. DM1 did not
inhibit major CYP450 enzymes in vitro.&nbsp; In human plasma, trastuzumab
emtansine catabolites MCC-DM1, Lys-MCC-DM1, and DM1 were detected at low levels.<i>&nbsp;
In vitro,</i> DM1 was a substrate of P-glycoprotein (P-gp).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Elimination</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Based on population
pharmacokinetic (PK) analysis, following intravenous administration of
trastuzumab emtansine in patients with HER2&#8209;positive metastatic breast
cancer, the clearance of trastuzumab emtansine was 0.68&nbsp;L/day and the
elimination half&#8209;life&nbsp;(t<sub>1/2</sub>) was
approximately&nbsp;4&nbsp;days. No accumulation of trastuzumab emtansine was
observed after repeated dosing of intravenous infusion every&nbsp;3&nbsp;weeks.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Based on population PK analysis, body weight, albumin, sum
of longest diameter of target lesions by Response Evaluation Criteria In Solid
Tumors<i> </i>(RECIST), HER2 shed extracellular domain (ECD), baseline
trastuzumab concentrations, and aspartate aminotransferase&nbsp;(AST) were
identified as statistically significant covariates for trastuzumab emtansine PK
parameters. However, the magnitude of effect of these covariates on trastuzumab
emtansine exposure suggests that these covariates are unlikely to have any
clinically meaningful effect on trastuzumab emtansine exposure. In addition,
exploratory analysis showed that the impact of covariates (i.e., renal function,
race and age) on the pharmacokinetics of total trastuzumab and DM1 was limited
and was not clinically relevant. In nonclinical studies, trastuzumab emtansine
catabolites including DM1, Lys&#8209;MCC&#8209;DM1, and MCC&#8209;DM1 are
mainly excreted in the bile with minimal elimination in urine.</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><u>Linearity/non-linearity</u></p>

<p class=MsoNormal>Trastuzumab emtansine when administered intravenously every
3&nbsp;weeks exhibited linear PK across doses ranging from 2.4 to
4.8&nbsp;mg/kg; patients who received doses less than or equal to
1.2&nbsp;mg/kg had faster clearance.</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><u>Elderly patients&nbsp; </u></p>

<p class=MsoNormal>The population PK analysis showed that age did not affect
the PK of trastuzumab emtansine. No significant difference was observed in the
PK of trastuzumab emtansine among patients &lt;&nbsp;65 years
(n&nbsp;=&nbsp;577), patients between 65&#8209;75 years (n&nbsp;=&nbsp;78) and
patients &gt;&nbsp;75&nbsp;years (n&nbsp;=&nbsp;16).</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u>Renal impairment </u></p>

<p class=MsoNormal>No formal PK study has been conducted in patients with renal
impairment. The population PK analysis showed that creatinine clearance does
not affect the PK of trastuzumab emtansine. Pharmacokinetics of trastuzumab
emtansine in patients with mild (creatinine clearance CLcr&nbsp;60 to
89&nbsp;mL/min,&nbsp;n&nbsp;=&nbsp;254) or moderate (CLcr&nbsp;30 to
59&nbsp;mL/min,&nbsp;n&nbsp;=&nbsp;53) renal impairment were similar to those
in patients with normal renal function (CLcr&nbsp;<span style='font-family:
Symbol'>&sup3;</span>&nbsp;90&nbsp;mL/min,&nbsp;n&nbsp;=&nbsp;361).
Pharmacokinetic data in patients with severe renal impairment (CLcr&nbsp;15 to
29&nbsp;mL/min) are limited (n&nbsp;=&nbsp;1), therefore no dosage
recommendations can be made.</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><b><u><span
 style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u>Hepatic
impairment </u></p>

<p class=MsoNormal>The liver is a primary organ for eliminating DM1 and
DM1-containing catabolites. The pharmacokinetics of trastuzumab emtansine and
DM1-containing catabolites were evaluated after the administration of 3.6 mg/kg
of trastuzumab emtansine to metastatic HER2+ breast cancer patients with normal
hepatic function (n=10), mild (Child-Pugh A; n=10) and moderate (Child-Pugh B;
n=8) hepatic impairment. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>- Plasma concentrations of DM1 and DM1-containing
catabolites (Lys-MCC-DM1 and MCC-DM1) were low and comparable between patients
with and without hepatic impairment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>- Systemic exposures (AUC) of trastuzumab emtansine at Cycle
1 in patients with mild and moderate hepatic impairment were approximately 38%
and 67% lower than that of patients with normal hepatic function, respectively.
Trastuzumab emtansine exposure (AUC) at Cycle 3 after repeated dosing in
patients with mild or moderate hepatic dysfunction was within the range
observed in patients with normal hepatic function.&nbsp; </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>No formal pharmacokinetic study has been conducted and no
population PK data was collected in patients with severe hepatic impairment
(Child-Pugh class C).</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Other special populations</u></p>

<p class=MsoNormal style='page-break-after:avoid'>The population PK analysis
showed that race did not appear to influence the PK of trastuzumab emtansine.
Because most of the patients in trastuzumab emtansine clinical studies were
females, the effect of gender on the PK of trastuzumab emtansine was not
formally evaluated.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u>Animal
toxicology and/or pharmacology</u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>Administration of trastuzumab emtansine was well tolerated
in rats and monkeys at doses up to 20 and 10&nbsp;mg/kg, respectively,
corresponding to 2040&nbsp;<span style='font-family:Symbol'>m</span>g DM1/m<sup>2</sup>
in both species, which&nbsp;is approximately equivalent to the clinical dose of
trastuzumab emtansine in patients.&nbsp; In the GLP toxicity studies, with the
exception of irreversible peripheral axonal toxicity (observed only in monkeys
at <span style='font-family:Symbol'>&sup3;</span>&nbsp;10 mg/kg) and
reproductive organ toxicity (observed only in rats at 60&nbsp;mg/kg), partially
or completely reversible dose dependent toxicities were identified in both
animal models. Principal toxicities included liver (liver enzyme elevations) at
<span style='font-family:Symbol'>&sup3;</span>&nbsp;20 mg/kg and <span
style='font-family:Symbol'>&sup3;</span>&nbsp;10 mg/kg, bone marrow (reduced
platelet and white blood cell count)/hematologic at <span style='font-family:
Symbol'>&sup3;</span>&nbsp;20 mg/kg and <span style='font-family:Symbol'>&sup3;</span>&nbsp;10
mg/kg, and lymphoid organs at <span style='font-family:Symbol'>&sup3;</span>&nbsp;20
mg/kg and&nbsp;<span style='font-family:Symbol'>&sup3;</span>&nbsp;3&nbsp;mg/kg,&nbsp;
in rat and monkey, respectively.</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><i>&nbsp;</i></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u>Mutagenicity</u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>DM1 was aneugenic or clastogenic in an <i>in vivo</i>
single-dose rat bone marrow micronucleus assay at exposures that were
comparable to mean maximum concentrations of DM1 measured in humans
administered trastuzumab emtansine. DM1 was not mutagenic in an <i>in vitro</i>
bacterial reverse mutation (Ames) assay.&nbsp; </p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'><b><u><span
 style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u>Impairment of fertility and teratogenicity</u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>No fertility studies in animals have been performed to
evaluate the effect of trastuzumab emtansine. However, based on results from
general animal toxicity studies, adverse effects on fertility can be expected.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Dedicated embryo&#8209;foetal development studies have not
been conducted in animals with trastuzumab emtansine. Developmental toxicity of
trastuzumab has been identified in the clinical setting although it was not
predicted in the non&#8209;clinical program. In addition, developmental
toxicity of maytansine has been identified in non&#8209;clinical studies which
suggests that DM1, the microtubule&#8209;inhibiting cytotoxic maytansinoid
component of trastuzumab emtansine, will be similarly teratogenic and
potentially embryotoxic.</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>Succinic
acid</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>Sodium
hydroxide</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>Sucrose</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>Polysorbate&nbsp;20</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</b></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal>This medicinal product must not be mixed or diluted with
other medicinal products except those mentioned in section&nbsp;6.6.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Glucose&nbsp;(5%) solution should not be used for
reconstitution or dilution since it causes aggregation of the protein.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf life</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Unopened vial</u></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>3&nbsp;years.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><u>Reconstituted solution</u></p>

<p class=MsoNormal style='page-break-after:avoid'><u>&nbsp;</u></p>

<p class=MsoNormal style='page-break-after:avoid'>Chemical and physical in&#8209;use
stability of the reconstituted solution has been demonstrated for up to
24&nbsp;hours at 2&deg;C&nbsp;to&nbsp;8&deg;C. From a microbiological point of
view, the product should be used immediately. If not used immediately, the
reconstituted vials can be stored for up to 24&nbsp;hours at
2&deg;C&nbsp;to&nbsp;8&deg;C, provided it was reconstituted under controlled
and validated aseptic conditions, and must be discarded thereafter.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Diluted solution </u></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal>The reconstituted Kadcyla solution diluted in infusion bags
containing sodium chloride 9&nbsp;mg/mL (0.9%) solution for infusion, or sodium
chloride 4.5&nbsp;mg/mL (0.45%) solution for infusion, is stable for up to
24&nbsp;hours at 2&deg;C&nbsp;to&nbsp;8&deg;C, provided it was prepared under
controlled and validated aseptic conditions. Particulates may be observed on
storage if diluted in 0.9% sodium chloride (see&nbsp;section&nbsp;6.6).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Store in a refrigerator (2<span style='font-family:Symbol'>&deg;</span>C&nbsp;&#8211;&nbsp;8<span
style='font-family:Symbol'>&deg;</span>C).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For storage conditions after reconstitution and dilution of
the medicinal product, see section&nbsp;6.3.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature
and contents of container </b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Kadcyla 100 mg powder for concentrate for solution for
infusion</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla is provided in 15&nbsp;mL (100 mg) Type 1 glass vial
closed with a grey-butyl rubber stopper coated with fluoro&#8209;resin laminate,
and sealed with an aluminium seal with a white plastic flip-off cap. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Pack of 1&nbsp;vial.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Kadcyla 160 mg powder for concentrate for solution for
infusion</u></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla is provided in 20 mL (160 mg) Type 1 glass vial
closed with a grey-butyl rubber stopper coated with fluoro resin laminate, and
sealed with an aluminium seal with a purple plastic flip-off cap.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Pack of 1 vial.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal and other handling</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>Appropriate aseptic technique should be used. Appropriate
procedures for the preparation of chemotherapeutic medicinal products should be
used.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The reconstituted Kadcyla solution should be diluted in
polyvinyl chloride (PVC) or latex&#8209;free PVC&#8209;free polyolefin infusion
bags.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The use of 0.20 or 0.22 micron in-line polyethersulfone
(PES) filter is required for the infusion when the concentrate for infusion is
diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. </p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal>In order to prevent medicinal product errors it is important
to check the vial labels to ensure that the medicinal product being prepared is
Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph'>&nbsp;</p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u>Instructions for reconstitution</u></p>

<p class=MsoNormal style='text-align:justify;text-justify:inter-ideograph;
page-break-after:avoid'><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='margin-left:17.85pt;text-align:justify;text-justify:
inter-ideograph;text-indent:-17.85pt;page-break-after:avoid'><span lang=ES
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; 100 mg trastuzumab
emtansine vial: Using a sterile syringe, slowly inject 5&nbsp;mL of sterile
water for injection into the vial. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-align:justify;text-justify:
inter-ideograph;text-indent:-17.85pt;page-break-after:avoid'><span lang=ES
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; 160 mg trastuzumab
emtansine vial: Using a sterile syringe, slowly inject 8&nbsp;mL of sterile
water for injection into the vial. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-align:justify;text-justify:
inter-ideograph;text-indent:-17.85pt;page-break-after:avoid'><span lang=ES
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Swirl the vial
gently until completely dissolved. Do not shake. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Reconstituted solution should be inspected visually for
particulate matter and discolouration prior to administration. The
reconstituted solution should be free of visible particulates, clear to
slightly opalescent. The colour of the reconstituted solution should be
colourless to pale brown. Do not use if the reconstituted solution contains
visible particulates, or is cloudy or discoloured.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><u>Instructions for dilution</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>Determine the volume of the reconstituted solution required
based on a dose of 3.6&nbsp;mg trastuzumab emtansine/kg body weight (see
section&nbsp;4.2):</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Volume</b>
(mL)&nbsp;=&nbsp;<i><u>Total dose to be administered</u></i><u> (<b>body weight</b>
(kg) x <b>dose</b> (mg/kg))</u> </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>20</b> (mg/mL, concentration of reconstituted solution)</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal>The appropriate amount of solution should be withdrawn from
the vial and added to an infusion bag containing 250&nbsp;mL of sodium chloride
4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9&nbsp;mg/mL (0.9%)
solution for infusion. Glucose&nbsp;(5%) solution should not be used (see
section&nbsp;6.2). Sodium chloride 4.5 mg/mL (0.45%) solution for infusion may
be used without a polyethersulfone (PES) 0.20 or 0.22&#8209;&#956;m in&#8209;line
filter. If sodium chloride 9 mg/mL (0.9%) solution for infusion is used for
infusion, a 0.20 or 0.22 micron in-line polyethersulfone (PES) filter is
required. Once the infusion is prepared it should be administered immediately.
Do not freeze or shake the infusion during storage. </p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><u>Disposal</u></p>

<p class=MsoNormal><u><span style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal>The reconstituted product contains no preservative and is
intended for single use only. Discard any unused portion.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Any unused medicinal product or waste material should be
disposed of in accordance with local requirements.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><b>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING AUTHORISATION HOLDER</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Roche Registration GmbH </p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>Germany</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>&nbsp;</span></p>

<p class=MsoNormal><b>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='color:black'>EU/1/13/885/001</span></p>

<p class=MsoNormal><span style='color:black'>EU/1/13/885/002</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</b></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal>Date of first authorisation: 15 November 2013</p>

<p class=MsoNormal>Date of latest renewal: 17 September 2018</p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal><i>&nbsp;</i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'>Detailed information on this
medicinal product is available on the website of the European Medicines Agency <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a><span
style='color:blue'>.</span></p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:13.0pt'><b>ANNEX
II</b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.4pt;line-height:
13.0pt'><b>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER OF THE
BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
13.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.9pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
13.0pt'><b>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
13.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
13.0pt'><b>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
13.0pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:77.95pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-35.45pt;line-height:
13.0pt'><b>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b><b>CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT&nbsp;
</b></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:13.0pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:13.0pt'><b>&nbsp;</b></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=AnnexHeading>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER OF THE
BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'><u>Name and address of the
manufacturer of the biological active substance</u></p>

<p class=MsoNormal style='margin-right:70.8pt;line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Lonza Ltd.<br>
Lonzastrasse<br>
CH-3930 Visp<br>
Switzerland</p>

<p class=MsoNormal style='line-height:13.0pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='line-height:13.0pt'><u>Name and address of the
manufacturer responsible for batch release</u></p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=DE>Roche Pharma AG<br>
Emil-Barell-Strasse 1<br>
D-79639 Grenzach-Whylen<br>
Germany</span></p>

<p class=MsoNormal style='line-height:13.0pt'><span lang=DE>&nbsp;</span></p>

<p class=MsoNormal style='line-height:13.0pt'>The printed package leaflet of
the medicinal product must state the name and address of the manufacturer
responsible for the release of the concerned batch.</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=AnnexHeading><a name="OLE_LINK2">B.</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE </p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'>Medicinal product subject to
restricted medical prescription (see Annex I: Summary of Product
Characteristics, section 4.2).</p>

<p class=MsoNormal style='line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='line-height:13.0pt'><b>&nbsp;</b></p>

<p class=AnnexHeading>C. &nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS AND
REQUIREMENTS OF THE MARKETING AUTHORISATION</p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:13.0pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Periodic
Safety Update Reports</b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'>The
requirements for submission of periodic safety update reports for this
medicinal product are set out in the list of Union reference dates (EURD list)
provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent
updates published on the European medicines web-portal.</p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=AnnexHeading>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT&nbsp; </p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'><u><span
 style='text-decoration:none'>&nbsp;</span></u></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:13.0pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Risk
Management Plan (RMP)</b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;line-height:13.0pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:13.0pt'>The MAH
shall perform the required pharmacovigilance activities and interventions
detailed in the agreed RMP presented in Module 1.8.2 of the Marketing
Authorisation and any agreed subsequent updates of the RMP.</p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt;page-break-after:
avoid'>An updated RMP should be submitted:</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;line-height:
13.0pt'><span lang=ES style='font-family:Symbol'>&middot;</span>&nbsp; At the
request of the European Medicines Agency;</p>

<p class=MsoNormal style='margin-left:35.7pt;text-indent:-17.85pt;line-height:
13.0pt'><span lang=ES style='font-family:Symbol'>&middot;</span>&nbsp; Whenever
the risk management system is modified, especially as the result of new information
being received that may lead to a significant change to the benefit/risk
profile or as the result of an important (pharmacovigilance or risk
minimisation) milestone being reached.</p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in;line-height:13.0pt;
page-break-after:avoid'><span lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>Additional
risk minimisation measures </b></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt;page-break-after:
avoid'>&nbsp;</p>

<p class=MsoNormal>The MAH shall agree the content and format of the Kadcyla (trastuzumab
emtansine) educational material and a communication plan with the National
Competent Authority in the Member State before Kadcyla (trastuzumab emtansine)
is launched in each Member State.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The MAH shall ensure that in parallel to the launch of Kadcyla
(trastuzumab emtansine), all health care professionals who may prescribe,
dispense or administer Kadcyla (trastuzumab emtansine) and/or Herceptin (trastuzumab)
are provided with a health care professional (HCP) educational pack.&nbsp; This
HCP educational pack shall consist of the following:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:38.25pt;text-indent:-17.85pt;line-height:
115%'><span lang=ES style='line-height:115%;font-family:Symbol'>&middot;</span><span
style='line-height:115%'>&nbsp;&nbsp;&nbsp; </span><span style='line-height:
115%'>Kadcyla (trastuzumab emtansine) SPC</span></p>

<p class=MsoNormal style='margin-left:38.25pt;text-indent:-17.85pt;line-height:
115%'><span lang=ES style='line-height:115%;font-family:Symbol'>&middot;</span><span
style='line-height:115%'>&nbsp;&nbsp;&nbsp; </span><span style='line-height:
115%'>Health care professional information </span></p>

<p class=MsoNormal>The HCP information shall contain the following key
messages:</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>1.&nbsp;&nbsp; Kadcyla (</span><span
style='line-height:115%'>trastuzumab emtansine)</span><span style='line-height:
115%'> and Herceptin (trastuzumab) are two very different products with
different active substances never to be used interchangeably.&nbsp; </span><span
style='line-height:115%'>Kadcyla (trastuzumab emtansine)</span><span
style='line-height:115%'> is NOT a generic version of Herceptin (trastuzumab) and
has different properties, indications and dose.</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>2.&nbsp;&nbsp; Trastuzumab emtansine is an
antibody-drug conjugate containing humanized anti-HER2 IgG1 antibody
trastuzumab and DM1, a microtubule-inhibitory maytansinoid. </span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>3.&nbsp;&nbsp; Do not substitute or
combine trastuzumab emtansine with or for trastuzumab</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>4.&nbsp;&nbsp; Do not administer trastuzumab
emtansine in combination with chemotherapy</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>5.&nbsp;&nbsp; Do not administer </span><span
style='line-height:115%'>trastuzumab emtansine</span><span style='line-height:
115%'> at doses greater than 3.6 mg/kg once every 3 weeks</span><span
style='line-height:115%'> </span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>6.&nbsp;&nbsp; If a prescription for
Kadcyla (trastuzumab emtansine) is written electronically, it is important to
ensure that the medicinal product prescribed is trastuzumab emtansine and not
trastuzumab. </span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>7.&nbsp;&nbsp; Both the invented name
Kadcyla<b> </b>and its full non-proprietary name (trastuzumab emtansine) should
be used and confirmed when prescribing, preparing the infusion solution and administering
Kadcyla (trastuzumab emtansine) to patients. It must be verified that the
non-proprietary name is trastuzumab emtansine.</span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>8.&nbsp;&nbsp; In order to prevent medicinal
product errors it is important to review the Summary of Product Characteristics
and to check the outer carton and vial labels to ensure that the medicinal
product being prepared and administered is Kadcyla (trastuzumab emtansine) and
not trastuzumab. </span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>9.&nbsp;&nbsp; Description of the key
differences between trastuzumab emtansine and trastuzumab in relation to
indication, dose, administration and packaging differences. </span></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt;line-height:
115%'><span style='line-height:115%'>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><b>Obligation to conduct
post-authorisation measures</b></p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'>The MAH shall complete, within
the stated timeframe, the below measures:</p>

<p class=MsoNormal style='text-autospace:none'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=453 valign=top style='width:339.95pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'>Description</p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'>Due date</p>
  </td>
 </tr>
 <tr>
  <td width=453 valign=top style='width:339.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Paragraph><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>PAES:
  In order to further investigate the efficacy of trastuzumab emtansine in the
  adjuvant treatment of adult patients with HER2-positive early breast cancer
  who have residual invasive disease, in the breast and/or lymph nodes, after
  neoadjuvant taxane-based and HER2-targeted therapy, the MAH should submit the
  final analysis of OS from the phase 3, randomised, open-label study KATHERINE
  (BO27938).</span></p>
  </td>
  <td width=151 valign=top style='width:113.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Paragraph><span style='font-size:11.0pt;font-family:"Times New Roman",serif'>30
  June 2024</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-.05pt;line-height:13.0pt'>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center'><b>ANNEX III</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>LABELLING AND
PACKAGE LEAFLET</b></p>

<p class=MsoNormal>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=Annex>A. LABELLING</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><b>CARTON </b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla 100&nbsp;mg powder for concentrate for solution for
infusion </p>

<p class=MsoNormal>trastuzumab emtansine</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>One vial of powder for concentrate for solution for infusion
contains 100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL
solution contains 20 mg/mL of trastuzumab emtansine.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
  OF EXCIPIENTS</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Excipients:</p>

<p class=MsoNormal>Succinic acid, sodium hydroxide, sucrose, polysorbate&nbsp;20.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Powder for concentrate for solution for infusion</p>

<p class=MsoNormal>1 vial of 100&nbsp;mg</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>For intravenous use after reconstitution and dilution</p>

<p class=MsoNormal>Read the package leaflet before use</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Cytotoxic</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>To be administered under the supervision of a physician
experienced in the use of cytotoxic agents.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><b>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Store in a refrigerator
(2&ordm;C &#8211; 8&ordm;C)</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><b>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS
  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM
  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE-CH>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal><span lang=DE-CH>Germany</span></p>

<p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>

<p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='color:black'>EU/1/13/885/001</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Batch</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Medicinal product subject to medical prescription</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
  ON USE</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='background:lightgrey'>Justification for not
including Braille accepted</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='background:lightgrey'>&lt;2D barcode carrying
the unique identifier included.&gt;</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN: </p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>MINIMUM PARTICULARS TO
APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>&nbsp;</b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>VIAL LABEL</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal>Kadcyla 100&nbsp;mg powder for concentrate for solution for
infusion</p>

<p class=MsoNormal>trastuzumab emtansine</p>

<p class=MsoNormal>Intravenous use</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For intravenous use after reconstitution and dilution</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>Lot</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>100&nbsp;mg</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</b></p>

</div>

<p class=MsoNormal style='background:white'><b>&nbsp;</b></p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</b></p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  <p class=MsoNormal><b>CARTON </b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
  OF THE MEDICINAL PRODUCT</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla 160&nbsp;mg powder for concentrate for solution for
infusion </p>

<p class=MsoNormal>trastuzumab emtansine</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
  OF ACTIVE SUBSTANCE(S)</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>One vial of powder for concentrate for solution for infusion
contains 160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL
solution contains 20 mg/mL of trastuzumab emtansine.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
  OF EXCIPIENTS</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Excipients:</p>

<p class=MsoNormal>Succinic acid, sodium hydroxide, sucrose, polysorbate 20.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
  FORM AND CONTENTS</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Powder for concentrate for solution for infusion</p>

<p class=MsoNormal>1 vial of 160&nbsp;mg</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
  AND ROUTE(S) OF ADMINISTRATION</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal>For intravenous use after reconstitution and dilution</p>

<p class=MsoNormal>Read the package leaflet before use</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH
  OF CHILDREN</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Keep out of the sight and reach of children</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
  SPECIAL WARNING(S), IF NECESSARY</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Cytotoxic</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>To be administered under the supervision of a physician
experienced in the use of cytotoxic agents.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
  DATE</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
  STORAGE CONDITIONS</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Store in a refrigerator (2&ordm;C &#8211; 8&ordm;C)</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;
  page-break-after:avoid'><b>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL PRECAUTIONS
  FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM
  SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
  AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span lang=DE-CH>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=DE-CH>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
  AUTHORISATION NUMBER(S)</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='color:black'>EU/1/13/885/002</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
  NUMBER</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Batch</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
  CLASSIFICATION FOR SUPPLY</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Medicinal product subject to medical prescription</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=619 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><b>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
  ON USE</b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;border:none;
padding:0in'><b>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION IN BRAILLE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='background:lightgrey'>Justification for not
including Braille accepted</span></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><span style='background:lightgrey'>&lt;2D barcode carrying
the unique identifier included.&gt;</span></p>

<p class=MsoNormal><span style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>PC: </p>

<p class=MsoNormal>SN: </p>

<p class=MsoNormal>NN: </p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>MINIMUM PARTICULARS TO
APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>&nbsp;</b></p>

<p class=MsoNormal style='border:none;padding:0in'><b>VIAL LABEL</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION</b></p>

</div>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal>Kadcyla 160&nbsp;mg powder for concentrate for solution for
infusion</p>

<p class=MsoNormal>trastuzumab emtansine</p>

<p class=MsoNormal>Intravenous use</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
OF ADMINISTRATION</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>For intravenous use after reconstitution and dilution</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>EXP</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>Lot</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONTENTS
BY WEIGHT, BY VOLUME OR BY UNIT</b></p>

</div>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>160&nbsp;mg</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:5.65pt'>&nbsp;</p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='border:none;padding:0in'><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER</b></p>

</div>

<p class=MsoNormal>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=Annex>B. PACKAGE LEAFLET</p>

<p class=MsoNormal>&nbsp;</p>

<span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center'><b>Package leaflet:
Information for the user</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>Kadcyla100&nbsp;mg
powder for concentrate for solution for infusion</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>Kadcyla
160&nbsp;mg powder for concentrate for solution for infusion</b></p>

<p class=MsoNormal align=center style='text-align:center'>trastuzumab emtansine</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Read all of this leaflet carefully before you start being
given this medicine because it contains important information for you.</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Keep this
leaflet. You may need to read it again.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; If you
have any further questions, ask your doctor, pharmacist or nurse.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; If you get
any side effects, talk to your doctor, pharmacist or nurse. This includes any
possible side effects not listed in this leaflet. See section 4.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>What is in this leaflet</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'>1.&nbsp;&nbsp; What
Kadcyla is and what it is used for</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'>2.&nbsp;&nbsp; What
you need to know before you are given Kadcyla</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'>3.&nbsp;&nbsp; How
you are given Kadcyla </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'>4.&nbsp;&nbsp; Possible
side effects</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'>5.&nbsp;&nbsp; How
to store Kadcyla</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'>6.&nbsp;&nbsp; Contents
of the pack and other information</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Kadcyla is
and what it is used for</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>What Kadcyla is</b></p>

<p class=MsoNormal>Kadcyla contains the active substance trastuzumab emtansine,
which is made up of two parts that are linked together:</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; trastuzumab
- a monoclonal antibody that binds selectively to an antigen (a target protein)
called human epidermal growth factor receptor 2 (HER2). HER2 is found in large
amounts on the surface of some cancer cells where it stimulates their growth.
When trastuzumab binds to HER2 it can stop the cancer cells growth and cause
them to die.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; DM1
&#8211; an anti-cancer substance that becomes active once Kadcyla enters the
cancer cell. </p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal><b>What Kadcyla is used for</b></p>

<p class=MsoNormal>Kadcyla is used to treat breast cancer in adults when:</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; the cancer
cells have many HER2 proteins on them - your doctor will test your cancer cells
for this. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; you have
already received the medicine trastuzumab and a medicine known as a taxane.</p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>the cancer has spread to areas near the breast or to other parts
of your body (metastasized)</p>

<p class=MsoListParagraph style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>the cancer has not spread to other parts of the body and
treatment is going to be given after surgery (treatment after surgery is called
adjuvant therapy).</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to
know before you are given Kadcyla</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>You must not be given Kadcyla</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; if you are
allergic to trastuzumab emtansine or any of the other ingredients of this
medicine (listed in section 6). </p>

<p class=MsoNormal>You should not be given Kadcyla if the above applies to you.
If you are not sure, talk to your doctor or nurse before you are given Kadcyla.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Warnings and precautions</b></p>

<p class=MsoNormal style='page-break-after:avoid'>Talk to your doctor or nurse
before you are given Kadcyla if:</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; you have
ever had a serious infusion-related reaction from using trastuzumab characterised
by symptoms such as flushing, chills, fever, shortness of breath, difficulty
breathing, rapid heartbeat or a drop in blood pressure.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; you are
receiving treatment with blood thinning medicines (e.g. warfarin, heparin).</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; you have
any history of liver problems. Your doctor will check your blood to test your
liver function before and regularly during treatment</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>If any of the above apply to you (or you are not sure), talk
to your doctor or pharmacist before you are given Kadcyla.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Look out for side effects</b></p>

<p class=MsoNormal>Kadcyla can make some existing conditions worse, or cause
side effects. See section&nbsp;4 for more details about what side effects to
look out for.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>Tell your doctor or nurse straight away if you notice any
of the following serious side effects while you are given Kadcyla:</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <b>Breathing
problems:</b> Kadcyla can cause serious breathing problems such as shortness of
breath (either at rest or while performing any type of activity) and
cough.&nbsp; These may be signs of inflammation of your lung, which may be
serious, and even fatal. If you develop lung disease your doctor may stop
treatment with this medicine.</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <b>Liver
problems: </b>Kadcyla can cause inflammation or damage to cells in the liver that
can stop the liver from functioning normally. Inflamed or injured liver cells
may leak higher than normal amounts of certain substances (liver enzymes) into
the bloodstream, resulting in elevated liver enzymes in blood tests. In most
cases you will not have any symptoms. Some symptoms could be yellowing of your
skin and whites of your eyes (jaundice). Your doctor will check your blood to
test your liver function before and regularly during treatment.</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:.25in'>Another rare abnormality that can
occur in the liver is a condition known as nodular regenerative hyperplasia
(NRH). This abnormality causes the structure of the liver to change and can
change how the liver functions. Over time, this may lead to symptoms such as a
bloated sensation or swelling of the abdomen due to fluid accumulation or
bleeding from abnormal blood vessels in the gullet or rectum.</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <b>Heart
problems: </b>Kadcyla can weaken the heart muscle. When the heart muscle is
weak, patients may develop symptoms such as shortness of breath at rest or when
sleeping, chest pain, swollen legs or arms, and a sensation of rapid or
irregular heartbeats. Your doctor will check your heart function before and
regularly during treatment. You should tell your doctor immediately if you
notice any of the above symptoms.</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <b>Infusion-related
reactions or allergic reactions</b>: Kadcyla can cause flushing, shivering
fits, fever, trouble breathing, low blood pressure, rapid heartbeat, sudden
swelling of your face, tongue, or trouble swallowing during the infusion or
after the infusion on the first day of treatment. Your doctor or nurse will
check to see whether you are having any of these side effects. If you develop a
reaction, they will slow down or stop the infusion and may give you treatment
to counteract the side effects. The infusion may be continued after the
symptoms improve.</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <b>Bleeding
problems:</b> Kadcyla can lower the number of platelets in your blood.
Platelets help your blood to clot so you might get unexpected bruising or
bleeding (such as nose bleeds, bleeding from gums). Your doctor will check your
blood regularly for decreased platelets. You should tell your doctor
immediately if you notice any unexpected bruising or bleeding.</p>

<p class=MsoNormal style='margin-left:.25in'>&nbsp;</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; <b>Neurological
problems:</b> Kadcyla can damage nerves. You may experience tingling, pain,
numbness, itching, crawling sensation, pins and needles in your hands and feet.
Your doctor will monitor you for signs and symptoms of neurological problems.<i>
</i></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'>Tell your
doctor or nurse straight away if you notice any of the side effects above.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Children and adolescents</b></p>

<p class=MsoNormal>Kadcyla is not recommended for anyone under the age of
18&nbsp;years. This is because there is no information on how well it works in
this age group.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Other medicines and Kadcyla</b></p>

<p class=MsoNormal>Tell your doctor or nurse if you are taking, have recently
taken or might take any other medicines. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In particular, tell your doctor or pharmacist if you are
taking:</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; any
medicines to thin your blood such as warfarin or decrease the ability to form
blood clot such as aspirin</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; medicines
for fungal infections called ketoconazole, itraconazole or voriconazole</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; antibiotics
for infections called clarithromycin or telithromycin</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; medicines
for HIV called atazanavir, indinavir, nelfinavir, ritonavir or saquinavir.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; medicine
for depression called nefazodone</p>

<p class=MsoNormal>If any of the above apply to you (or you are not sure), talk
to your doctor or pharmacist before you are given Kadcyla.&nbsp; </p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>Pregnancy</b></p>

<p class=MsoNormal>Kadcyla is not recommended if you are pregnant because this medicine
may cause harm to the unborn baby. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Tell your
doctor before using Kadcyla if you are pregnant, think you may be pregnant or
are planning to have a baby.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Use
effective contraception to avoid becoming pregnant while you are being treated
with Kadcyla. Talk to your doctor about the best contraception for you.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; You should
continue to take your contraception for at least 7 months after your last dose
of Kadcyla. Talk to your doctor before stopping your contraception. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Male
patients or their female partners should also use effective contraception. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; If you do
become pregnant during treatment with Kadcyla, tell your doctor straight away.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>Breast-feeding</b></p>

<p class=MsoNormal>You should not breast-feed during treatment with Kadcyla.
Also you should not breast-feed for&nbsp;7 months after your last infusion of
Kadcyla. It is not known whether the ingredients in Kadcyla pass into
breast-milk. Talk to your doctor about this.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Driving and using machines</b></p>

<p class=MsoNormal>It is not expected that Kadcyla will affect your ability to
drive, cycle, use tools or machines. If you experience flushing, shivering
fits, fever, trouble breathing, low blood pressure or a rapid heartbeat
(infusion-related reaction), blurred vision, tiredness, headache, or dizziness,
do not drive, cycle, use tools or machines until these reactions stop.</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal><b>Important information about some of the ingredients of
Kadcyla</b></p>

<p class=MsoNormal>This medicine contains less than 1 mmol sodium (23 mg) per
dose. It is essentially &#8216;sodium- free&#8217;.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How you are given
Kadcyla</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'>Kadcyla
will be given to you by a doctor or nurse in a hospital or clinic:</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; It is
given by a drip into a vein (intravenous infusion).</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; You will
be given one infusion every&nbsp;3&nbsp;weeks.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>How much you will be given</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; You will
be given 3.6&nbsp;mg of Kadcyla for every kilogram of your body weight. Your
doctor will calculate the correct dose for you.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; The first
infusion will be given to you over 90&nbsp;minutes. You will be observed by a
doctor or nurse while it is being given and for at least 90&nbsp;minutes
following the initial dose, in case you have any side effects. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; If the
first infusion is well tolerated, the infusion on your next visit may be given
over 30&nbsp;minutes. You will be observed by a doctor or nurse while it is
being given and for at least 30&nbsp;minutes following the dose, in case you
have any side effects.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; The total
number of infusions that you will be given depends on how you respond to the
treatment and which indication is treated.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; If you
experience side effects, your doctor may decide to continue your treatment but
lower your dose, delay the next dose or stop the treatment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>If you miss a Kadcyla treatment</b></p>

<p class=MsoNormal>If you forget or miss your Kadcyla appointment, make another
appointment as soon as possible. Do not wait until your next planned visit. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>If you stop Kadcyla treatment</b></p>

<p class=MsoNormal>Do not stop treatment with this medicine without talking to
your doctor first.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>If you have any further questions on the use of this
medicine, ask your doctor or nurse. </p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Like all medicines, this medicine can cause side effects,
although not everybody gets them.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Tell your doctor or nurse straight away if you notice any
of following serious side effects.</b></p>

<p class=MsoNormal style='margin-top:6.0pt'><b>Very common (may affect more
than 1 in 10 people):</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Kadcyla
may cause inflammation or damage to cells in the liver, resulting in elevated
liver enzymes in blood tests. However, in most cases during Kadcyla treatment,
liver enzyme levels are elevated mildly and temporarily, do not cause any
symptoms, and do not affect liver function.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Unexpected
bruising and bleeding (such as nose bleeds).</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Tingling,
pain, numbness, itching, crawling sensation, pins and needles in your hands and
feet. These symptoms may indicate nerve damage.</p>

<p class=MsoNormal style='margin-top:6.0pt'><b>Common (may affect up to 1 in 10
people):</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Flushing,
shivering fits, fever, trouble breathing, low blood pressure or a rapid
heartbeat during the infusion or up to 24 hours after the infusion &#8211;
these are so-called infusion-related reactions. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Heart
problems can occur. Most patients will not have symptoms from the heart
problems. If symptoms do occur, cough shortness of breath at rest or when
sleeping flat, chest pain and swollen ankles or arms, a sensation of rapid or
irregular heartbeats may be observed. </p>

<p class=MsoNormal style='margin-top:6.0pt'><b>Uncommon (may affect up to 1 in
100 people):</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Inflammation
of your lungs can cause breathing problems such as shortness of breath (either
at rest or while performing any type of activity), coughing or coughing spells
with a dry cough &#8211; these are signs of inflammation of your lung tissue.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Your skin
and whites of your eyes get yellow (jaundice) &#8211; these could be signs of
severe liver damage.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Allergic
reactions can occur and most patients will have mild symptoms such as itching
or tightness in the chest. In more severe cases, swelling of your face or
tongue, trouble swallowing or difficulty breathing may occur. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Tell your doctor or nurse straight away if you notice any of
the serious side effects above.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Other side effects include</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal><b>Very common:</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; decreased
red blood cells (shown in a blood test)</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; being sick
(vomiting)</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; diarrhoea </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; dry mouth</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; urinary
tract infection</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; constipation</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; stomach
ache</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; cough</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; shortness
of breath</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; inflammation
of the mouth</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; difficulty
sleeping</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; muscle or joint
pain</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; fever</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; headache</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; feeling
tired</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; weakness</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>Common</b><b>:</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; chills or
flu like symptoms </p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>decrease in your potassium levels (shown in a blood test)</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>skin rashes</p>

<p class=MsoNormal style='margin-left:.25in;text-indent:-.25in'><span
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>decreased white blood cells (shown in a blood test)</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; dry eyes,
watery eyes or blurred vision</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; eye
redness or infection</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; indigestion</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; swelling
of legs and/or arms</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; bleeding
from the gums</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; increase
in blood pressure </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; feeling
dizzy</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; taste
disturbances</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; itching</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; difficulty
in remembering</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; hair loss</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; hand-and-foot
skin reaction (Palmar-plantar erythrodysaesthesia syndrome)</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; nail
disorder</p>

<p class=MsoNormal style='page-break-after:avoid'><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>Uncommon:</b></p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Another
abnormality that can be caused by Kadcyla is a condition known as nodular
regenerative hyperplasia of the liver. This abnormality causes the structure of
the liver to change. Patients develop multiple nodules in the liver that can
change how the liver functions. Over time, this may lead to symptoms such as a
bloated sensation or swelling of the abdomen due to fluid accumulation or
bleeding from abnormal blood vessels in the gullet or rectum.</p>

<p class=MsoNormal style='margin-left:28.1pt;text-indent:-28.1pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If
the Kadcyla infusion solution leaks into the area around the infusion site you
may develop tenderness or redness of your skin, or swelling at the infusion
site. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>If you get any of the side effects after your treatment with
Kadcyla has stopped, talk to your doctor or nurse and tell them that you have
been treated with Kadcyla.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Reporting of side effects</b></p>

<p class=MsoNormal>If you get any side effects, talk to your doctor or nurse.
This includes any possible side effects not listed in this leaflet. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>You can also report side effects directly via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="https://www.ema.europa.eu/documents/template-form/appendix-v-adverse-drug-reaction-reporting-details_en.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='color:#3366FF'>.</span>
By reporting side effects you can help provide more information on the safety
of this medicine.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal style='page-break-after:avoid'><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Kadcyla</b></p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>Kadcyla will be stored by the
health professionals at the hospital or clinic.</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep
this medicine out of the sight and reach of children.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do
not use this medicine after the expiry date which is stated on the outer carton
and vial after EXP. The expiry date refers to the last day of that month.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store
in a refrigerator at (2&deg;C &#8209; 8&deg;C). Do not freeze.</p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When
prepared as a solution for infusion Kadcyla is stable for up to 24 hours at
2&deg;C&nbsp;to&nbsp;8&deg;C, and must be discarded thereafter. </p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do
not throw away any medicines via wastewater or household waste. Ask your
pharmacist how to dispose of medicines you no longer use. These measures will
help to protect the environment.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</b></p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>What Kadcyla contains</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; The active
substance is trastuzumab emtansine. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;  Kadcyla
100mg: One vial of powder for concentrate for solution for infusion contains
100 mg of trastuzumab emtansine. After reconstitution one vial of 5 mL solution
contains 20 mg/mL of trastuzumab emtansine.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Kadcyla
160mg: One vial of powder for concentrate for solution for infusion contains
160 mg of trastuzumab emtansine. After reconstitution one vial of 8 mL solution
contains 20 mg/mL of trastuzumab emtansine.</p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; The other
ingredients are succinic acid, sodium hydroxide (see section 2 under
&#8216;Important information about some of the ingredients of Kadcyla&#8217;),
sucrose, and polysorbate&nbsp;20.</p>

<p class=MsoNormal><b>&nbsp;</b></p>

<p class=MsoNormal><b>What Kadcyla looks like and contents of the pack</b></p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Kadcyla is
a white to off-white lyophilised powder for concentrate for solution for
infusion supplied in glass vials. </p>

<p class=MsoNormal style='margin-left:17.85pt;text-indent:-17.85pt'><span
lang=ES style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp; Kadcyla is
available in packs containing 1 vial.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><b>Marketing Authorisation Holder</b></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>Roche Registration GmbH </span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Manufacturer</b></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=DE-CH>Roche Pharma
AG</span></p>

<p class=MsoNormal><span lang=DE-CH>Emil-Barell-Strasse 1</span></p>

<p class=MsoNormal><span lang=EN-CARRIBEAN>D-79639 Grenzach-Wyhlen</span></p>

<p class=MsoNormal>Germany</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'>For any information about
this medicine, please contact the local representative of the Marketing
Authorisation Holder:</p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-CH>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR-CH>N.V. Roche S.A.</span></p>
  <p class=MsoNormal><span lang=FR>T&eacute;l/Tel: +32 (0) 2 525 82 11</span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=FR>&nbsp;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><b>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</b></p>
  <p class=MsoNormal>&#1056;&#1086;&#1096; &#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;
  &#1045;&#1054;&#1054;&#1044;</p>
  <p class=MsoNormal>&#1058;&#1077;&#1083;<span lang=FR>: +359 2&nbsp;818 44 44</span></p>
  <p class=MsoNormal><b><span lang=FR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=DE>UAB &#8220;Roche Lietuva&#8221;</span></p>
  <p class=MsoNormal><span lang=DE>Tel: +370 5 2546799</span></p>
  <p class=MsoNormal><b><span lang=DE-CH>&nbsp;</span></b></p>
  <p class=MsoNormal><b><span lang=DE-CH>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>(Voir/siehe Belgique/Belgien)</span></p>
  <p class=MsoNormal><b><span lang=DE-CH>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>&#268;esk&aacute; republika</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche s. r. o.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +420 - 2 20382111</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche (Magyarorsz&aacute;g) Kft.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +36 - 23 446 800</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Danmark</b></p>
  <p class=MsoNormal>Roche a/s</p>
  <p class=MsoNormal>Tlf: +45 - 36 39 99 99</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Malta</b></p>
  <p class=MsoNormal style='text-autospace:none'>(See Ireland)</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Pharma AG</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +49 (0) 7624 140</span></p>
  <p class=MsoNormal><b><span lang=DE>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Nederland B.V.</span></p>
  <p class=MsoNormal>Tel: +31 (<span style='layout-grid-mode:line'>0) 348
  438050</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Eesti</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Eesti O&Uuml;</span></p>
  <p class=MsoNormal><span lang=IT>Tel: + 372 - 6 177 380</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='layout-grid-mode:line'>Norge</span></b></p>
  <p class=MsoNormal><span style='layout-grid-mode:line'>Roche Norge AS</span></p>
  <p class=MsoNormal><span style='layout-grid-mode:line'>Tlf: +47 - 22 78 90 00</span></p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>&#917;&#955;&#955;&#940;&#948;&#945;</b></p>
  <p class=MsoNormal>Roche (Hellas) A.E. </p>
  <p class=MsoNormal>&#932;&#951;&#955;: +30 210 61 66 100</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Austria GmbH</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +43 (0) 1 27739</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal><span lang=ES>Roche Farma S.A.</span></p>
  <p class=MsoNormal>Tel: +34 - 91 324 81 00</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Polska</b></p>
  <p class=MsoNormal>Roche Polska Sp.z o.o.</p>
  <p class=MsoNormal>Tel: +48 - 22 345 18 88</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>France</b></p>
  <p class=MsoNormal>Roche</p>
  <p class=MsoNormal>T&eacute;l: +33&nbsp;(0)1 47 61 40 00</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR>Portugal</span></b></p>
  <p class=MsoNormal><span lang=PT-BR>Roche Farmac&ecirc;utica Qu&iacute;mica,
  Lda</span></p>
  <p class=MsoNormal><span lang=PT-BR>Tel: +351 - 21 425 70 00</span></p>
  <p class=MsoNormal><span lang=PT-BR>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Hrvatska</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche d.o.o</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel:&nbsp; +385 1 4722 333</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:13.0pt'><b><span lang=IT>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Rom&acirc;nia S.R.L.</span></p>
  <p class=MsoNormal>Tel: +40 21 206 47 01</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Ireland</b></p>
  <p class=MsoNormal>Roche Products (Ireland) Ltd.</p>
  <p class=MsoNormal>Tel: +353 (0) 1 469 0700</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Slovenija</b></p>
  <p class=MsoNormal>Roche farmacevtska dru&#382;ba d.o.o.</p>
  <p class=MsoNormal>Tel: +386 - 1 360 26 00</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PT-BR style='layout-grid-mode:line'>&Iacute;sland
  </span></b></p>
  <p class=MsoNormal><span lang=PT-BR style='layout-grid-mode:line'>Roche a/s</span></p>
  <p class=MsoNormal><span lang=PT-BR>c/o Icepharma hf</span></p>
  <p class=MsoNormal><span lang=PT-BR>S&iacute;mi<span style='layout-grid-mode:
  line'>: +354 540 8000</span></span></p>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT-BR>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Slovensk&aacute; republika </span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Slovensko, s.r.o.</span></p>
  <p class=MsoNormal>Tel: +421 - 2 52638201</p>
  <p class=MsoNormal><b>&nbsp;</b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Italia</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche S.p.A.</span></p>
  <p class=MsoNormal><span lang=DE-CH>Tel: +39 - 039 2471</span></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=DE-CH>Roche Oy<span style='layout-grid-mode:
  line'> </span></span></p>
  <p class=MsoNormal><span lang=DE-CH>Puh/Tel: +358 (0) 10 554 500</span></p>
  <p class=MsoNormal><span lang=DE-CH>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE-CH>K</span></b><b><span lang=EL>&#973;&#960;&#961;&#959;&#962;</span></b><span
  lang=EL> </span></p>
  <p class=MsoNormal><span lang=EL>&#915;.&#913;.&#931;&#964;&#945;&#956;&#940;&#964;&#951;&#962;
  &amp; &#931;&#953;&#945; &#923;&#964;&#948;.</span></p>
  <p class=MsoNormal>&#932;&#951;&#955;: +357 - 22 76 62 76</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>Sverige</b></p>
  <p class=MsoNormal>Roche AB</p>
  <p class=MsoNormal>Tel: +46 (0) 8 726 1200</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT>Latvija</span></b></p>
  <p class=MsoNormal><span lang=IT>Roche Latvija SIA</span></p>
  <p class=MsoNormal><span lang=IT>Tel: +371 - 6 7039831</span></p>
  <p class=MsoNormal><b><span lang=IT>&nbsp;</span></b></p>
  </td>
  <td width=306 valign=top style='width:229.5pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b>United Kingdom</b></p>
  <p class=MsoNormal>Roche Products Ltd.</p>
  <p class=MsoNormal>Tel: +44 (0) 1707 366000</p>
  <p class=MsoNormal>&nbsp;</p>
  </td>
 </tr>
</table>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>This leaflet was last
revised in </b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b>Other
sources of information</b></p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

<p class=MsoNormal style='margin-right:-.1pt'>Detailed information on this
medicine is available on the European Medicines Agency web site: <a
href="http://www.ema.europa.eu">http://www.ema.europa.eu</a><span
style='color:blue'>.</span> </p>

<b><span style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='margin-right:-.1pt'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-right:-.1pt;page-break-after:avoid'><b>The
following information is intended for medical or healthcare professionals only:
</b></p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>In order to prevent medicinal product errors it is important
to check the vial labels to ensure that the medicinal product being prepared is
Kadcyla (trastuzumab emtansine) and not Herceptin (trastuzumab).</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Kadcyla must be reconstituted and diluted by a healthcare
professional and administered as an intravenous infusion. It must not be
administered as an intravenous push or bolus.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Always keep this medicine in the closed original pack at a
temperature of 2&ordm;C &#8211; 8 &ordm;C in a refrigerator. A vial of Kadcyla
reconstituted with water for injections (not supplied) is stable for 24 hours
at </p>

<p class=MsoNormal>2&ordm;C &#8211; 8 &ordm;C after reconstitution and must not
be frozen. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Appropriate aseptic technique should be used. Appropriate
procedures for the preparation of chemotherapeutic medicinal products should be
used. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The reconstituted Kadcyla solution should be diluted in
polyvinyl chloride (PVC) or latex&#8209;free PVC&#8209;free polyolefin infusion
bags.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>The use of 0.20 or 0.22 micron in-line polyethersulfone
(PES) filter is required for the infusion when the concentrate for infusion is
diluted with sodium chloride 9 mg/mL (0.9%) solution for infusion. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Instructions for reconstitution</i></p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-22.5pt'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Kadcyla
100mg</u>: using a sterile syringe, slowly inject 5&nbsp;mL of sterile water
for injection into the 100&nbsp;mg trastuzumab emtansine vial. </p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-22.5pt'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Kadcyla
160mg</u>: using a sterile syringe, slowly inject 8&nbsp;mL of sterile water
for injection into the 160 mg trastuzumab emtansine vial.</p>

<p class=MsoNormal style='margin-left:22.5pt;text-indent:-22.5pt'><span
style='font-family:Symbol'>&middot;</span>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swirl
the vial gently until completely dissolved. Do not shake. </p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Reconstituted solution should be inspected visually for
particulate matter and discolouration prior to administration. The
reconstituted solution should be free of visible particulates, clear to
slightly opalescent. The colour of the reconstituted solution should be
colourless to pale brown. Do not use if reconstituted solution is cloudy or
discoloured.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal>Discard any unused portion. The reconstituted product contains
no preservative and is intended for single use only.</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal><i>Instructions for dilution</i></p>

<p class=MsoNormal>Determine the volume of the reconstituted solution required
based on a dose of 3.6&nbsp;mg trastuzumab emtansine/kg body weight:</p>

<p class=MsoNormal>&nbsp;</p>

<p class=MsoNormal style='page-break-after:avoid'><b>Volume</b>
(mL)&nbsp;=&nbsp;<i><u>Total dose to be administered</u></i><u> =(<b>body
weight</b> (kg) x <b>dose</b> (mg/kg))</u> </p>

<p class=MsoNormal style='page-break-after:avoid'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<b>20</b> (mg/mL, concentration of reconstituted solution)</p>

<p class=MsoNormal><b><u><span style='text-decoration:none'>&nbsp;</span></u></b></p>

<p class=MsoNormal>The appropriate amount of solution should be withdrawn from
the vial and added to an infusion bag containing 250&nbsp;mL of sodium chloride
4.5 mg/mL (0.45%) solution for infusion or sodium chloride 9&nbsp;mg/mL (0.9%)
solution for infusion. Glucose&nbsp;(5%) solution should not be used Sodium
chloride 4.5&nbsp;mg/mL (0.45%) solution for infusion may be used without a
polyethersulfone (PES) 0.20 or 0.22&#8209;&#956;m in&#8209;line filter. If
sodium chloride 9 mg/mL (0.9%) solution for infusion is used for infusion, a
0.20 or 0.22 micron in-line polyethersulfone (PES) filter is required. Once the
infusion is prepared it should be administered immediately. Do not freeze or
shake the infusion during storage. If diluted aseptically, it may be stored for
up to 24&nbsp;hours at 2&deg;C&nbsp;to&nbsp;8&deg;C.</p>

<p class=MsoNormal style='margin-right:-.1pt'>&nbsp;</p>

</div>

</body>

</html>
